# Title:

Leveraging DNA Methylation to Predict Treatment Response in Major Depressive

Disorder: A Critical Review

#### Authors:

Jan Dahrendorff<sup>1</sup>, Glenn Currier<sup>2</sup>, Monica Uddin<sup>1</sup>

#### Affiliations:

- 1. Genomics Program, College of Public Health, University of South Florida, Tampa, FL, USA
- Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, FL, USA

# **Corresponding author:**

Address correspondence to: Monica Uddin, PhD University of South Florida 3720 Spectrum Blvd., Suite 304 813-974-9765 monica43@usf.edu

#### Abstract

*Background*: Major depressive disorder (MDD) is a debilitating and prevalent mental disorder with a high disease burden. Despite a wide array of different treatment options, many patients do not respond to initial treatment attempts. Selection of the most appropriate treatment remains a significant clinical challenge in psychiatry, highlighting the need for the development of biomarkers with predictive utility. Recently, the epigenetic modification DNA methylation (DNAm) has emerged to be of great interest as a potential predictor of MDD treatment outcomes. Here we review efforts to date that seek to identify DNAm signatures associated with treatment response in individuals with MDD.

*Methods:* Searches were conducted in the databases PubMed, Scopus, and Web of Science with the concepts and keywords major depressive disorder, DNA methylation, antidepressants, psychotherapy, cognitive behavior therapy, electroconvulsive therapy, transcranial magnetic stimulation, and brain stimulation therapies.

*Results:* We identified 31 studies implicating DNAm patterns associated with MDD treatment outcomes. The majority of studies (N=25) are focused on selected target genes exploring treatment outcomes in pharmacological treatments (N=22) with a few studies assessing treatment response to electroconvulsive therapy (N=3). Additionally, there are few genome-scale efforts (N=6) to characterize DNAm patterns associated with treatment outcomes.

*Limitations:* There is a relative dearth of studies investigating DNAm patterns in relation to psychotherapy, electroconvulsive therapy, or transcranial magnetic stimulation; importantly, most existing studies have limited sample sizes.

Conclusions: Given the heterogeneity in both methods and results of studies to date,

there is a need for additional studies before existing findings can inform clinical

decisions.

Keywords: MDD, DNA methylation, treatment response

### 1 1. Introduction

Major depressive disorder (MDD) is a debilitating and highly prevalent mental 2 disorder characterized by a range of symptoms including depressed mood, loss of 3 4 interest in activities that once brought enjoyment, impairment of cognitive functioning, fatigue, sleep disturbances, and psychomotor changes (Association, 2013). MDD is the 5 6 most prevalent mental health disorder in the United States with current estimates of the 7 past year and lifetime prevalence of around 10% and 20%, respectively (Goodwin et al., 8 2022; Hasin et al., 2018). Globally, the World Health Organization estimates a lifetime 9 prevalence of 4.4% making MDD also the most common mental disorder (World Health 10 Organization, 2017). MDD is highly recurrent (Hardeveld et al., 2013; Moffitt et al., 2010) and associated with a substantial disease burden (Jia, Zack, Thompson, Crosby, 11 & Gottesman, 2015). Many people suffering from the disorder can face a reduction in 12 quality-adjusted life expectancy of around 30 years; as such, MDD is among the 13 diseases with the highest loss of quality-adjusted life expectancy (Jia et al., 2015). 14 Additionally, individuals suffering from MDD are at an increased risk to develop a range 15 of comorbidities (Arnaud et al., 2022) including cardiovascular diseases (Brunner et al., 16 2014; Surtees et al., 2008), metabolic disorders (Rotella & Mannucci, 2013; 17 18 Vancampfort et al., 2015), neurodegenerative diseases (Diniz, Butters, Albert, Dew, & 19 Reynolds, 2013; Ownby, Crocco, Acevedo, John, & Loewenstein, 2006), and autoimmune disorders(Andersson et al., 2015). 20

Although there have been significant efforts to illuminate the molecular
 underpinnings of MDD, the etiology of MDD remains poorly understood. Despite the role

of genetic factors in the etiology of MDD (reviewed in (Flint, 2023; Shadrina, 23 Bondarenko, & Slominsky, 2018)) the identified heritability estimates--around 40% 24 (Kendler, Gatz, Gardner, & Pedersen, 2006; Kendler, Ohlsson, Lichtenstein, Sundquist, 25 26 & Sundquist, 2018) -- are lower in comparison to other psychiatric disorders (e.g. schizophrenia 81%, Sullivan et al., 2003; bipolar disorder 85% (McGuffin et al., 2003) 27 and ADHD 82% (Chang, Lichtenstein, Asherson, & Larsson, 2013))suggesting that 28 29 additional factors beyond DNA sequence might mediate MDD pathogenesis. Recent work has proposed that epigenetic mechanisms play a role in mediating the risk of MDD 30 after environmental exposures (Klengel & Binder, 2015). Broadly, epigenetic alterations 31 32 influence gene expression and translation via chemical modifications that regulate either chromatin structure or modify the accessibility of DNA, resulting in altered transcriptional 33 activity of the locus (J. K. Kim, Samaranayake, & Pradhan, 2009). These processes 34 include DNA methylation (DNAm), histone modifications, and small non-coding RNAs. 35 among others. Among known epigenetic mechanisms, DNAm is perhaps the most 36 studied epigenetic modification. A large body of literature documents a range of 37 environmental factors that can lead to changes in DNAm patterns including exposure to 38 pollutants and toxins (Hou, Zhang, Wang, & Baccarelli, 2012), smoking (Breitling, Yang, 39 Korn, Burwinkel, & Brenner, 2011) aging (Bjornsson et al., 2008; Wong et al., 2010), 40 diet (summarized here (Maugeri & Barchitta, 2020)), medication (Kringel, Malkusch, & 41 Lotsch, 2021; Lotsch et al., 2013) physical activity (Sailani et al., 2019), early life 42 experiences (Cecil, Zhang, & Nolte, 2020; Klengel et al., 2013; Martins et al., 2021; 43 Weaver, Meaney, & Szyf, 2006) and stress exposure(van der Knaap et al., 2014). 44 Similarly, aberrant DNAm can modulate the transcriptional activity of genes, enabling 45 variation in gene expression patterns that can potentially mediate how an individual 46

47	responds to environmental stimuli (Provencal et al., 2020) or even contribute to the
48	pathogenesis of diseases (Nishiyama & Nakanishi, 2021; van den Oord et al., 2022).
49	DNAm has emerged to be of interest as a predictive molecular biomarker in MDD
50	treatment response (Gasso et al., 2017; Neyazi et al., 2018; Wang, Zhang, et al., 2018).
51	In such pharmaco-epigenetic studies, DNAm is measured in patients before, and in
52	some efforts, also post-completion of the treatment. In parallel, repeated depression
53	symptom measures are obtained throughout the treatment. The assessment of DNAm
54	at baseline and after completion of the treatment can thereby be utilized to characterize
55	epigenomic variation associated with treatment outcomes and in turn, inform the
56	development of tools with predictive utility (Domschke et al., 2014; Ju et al., 2019; L. Li
57	et al., 2021; Takeuchi et al., 2017). Advancing the development of such predictive tools
58	could potentially guide future treatment decisions and ultimately shift trial-and-error
59	treatment approaches toward more optimal treatment choices.
60	Several pharmacological and non-pharmacological treatment options for MDD
61	are currently available including pharmacotherapy, psychotherapy, and brain stimulation
62	treatments (Reviewed in (Gartlehner et al., 2017; Meerman, Ter Hark, Janzing, &
63	Coenen, 2022)), and often a combination of such treatments is utilized to maximize
64	treatment outcomes. Despite the variety of existing MDD therapeutics, a large
65	proportion of patients do not respond to initial treatment attempts (Trivedi et al., 2006;
66	Wang, Zhang, et al., 2018), with treatments leading to remission in only approximately
67	one-third of the patients (Trivedi et al., 2006; Undurraga & Baldessarini, 2012; Warden,
68	Rush, Trivedi, Fava, & Wisniewski, 2007). Similarly, between a third and 55% of

69 patients with MDD are classified as suffering from treatment-resistant depression, a

70 particularly severe form of depression in which two or more treatment attempts with antidepressant medication have previously been unsuccessful (Souery et al., 2007; 71 Thomas et al., 2013; Trivedi et al., 2006). Identification of the right treatment for a 72 73 patient is largely based on trying out different treatments, which usually takes a long time to achieve a clinical response in the patient, often times causing substantial 74 hardship to those seeking relief from their symptoms (Garcia-Gonzalez et al., 2017; 75 76 Papakostas, 2008) (Figure 1 for Illustration). The ability to provide treatments that are most likely to elicit a positive response in any individual patient remains an elusive goal 77 in psychiatry that could perhaps be informed by findings from DNAm studies. To 78 79 advance this goal, here, we review and summarize existing studies investigating DNAmbased epigenetic signatures associated with treatment outcomes in patients with MDD. 80 Given that the majority of epigenetic studies in relation to treatment outcomes are 81 examining DNAm, we will focus our review on this particular epigenetic modification. 82

- 83
- 84

#### 2. Materials and Method

The searches for this review were conducted in the databases PubMed (United 85 States National Library of Medicine at the National Institute of health), Scopus 86 (Elsevier), and Web of Science (Clarivate) to identify primary research articles on 87 DNAm associated with treatment response in MDD. The following search terms for this 88 review included: Major depressive disorder, DNA methylation, antidepressants, 89 psychotherapy, cognitive behavior therapy, brain stimulation therapy, electroconvulsive 90 therapy (ECT), and transcranial magnetic stimulation (TMS). The search included 91 92 primary research articles in English. Studies focusing on epigenetic mechanisms other than DNAm, conference abstracts, review papers, murine and cell culture studies 93 investigating DNAm associated with treatment responses were excluded from the 94

search. The searches in PubMed were conducted on September 7<sup>th</sup>, 2023, while the 95 Scopus and Web of Science searches were conducted on September 7<sup>th</sup>, 2023. 96 The PubMed search identified 52 articles; Scopus yielded 48 articles while Web 97 98 of Science returned 49 results. Additionally, two records that were identified in the reference list of a previous review paper were considered significant and subsequently 99 added to the search results. In total, 151 articles were identified and imported into 100 101 EndNote reference management software (Clarivate). After the removal of duplicated articles, 54 articles remained for initial review. Next, review articles, book chapters, case 102 reports, case studies, and murine and cell culture studies were removed after screening 103 104 the titles. Additionally, studies focused on characterizing DNAm alterations induced by MDD treatments that have not assessed treatment outcomes, and studies focused on 105 other psychiatric disorders were excluded from our results. This filtering procedure 106 107 removed 21 sources, producing a total of 33 primary research articles that underwent a full-text review. The full-text review led to the exclusion of two additional articles: One 108 literature review and one article not evaluating treatment outcomes, leaving 31 research 109 articles for inclusion in the study (Figure 2 for illustration of literature search). 110

### 111 **3. Results**

129

112	Figure 3 presents the results of the literature search process employed in this study.
113	Table 1 presents a summary of all studies included in this review. To date, most
114	epigenetic investigations ( $N = 25$ ) of MDD treatment responses are focused on selected
115	target genes that have been well characterized in the context of MDD including solute
116	carrier family 6 member 4 (SLC6A4), brain-derived neurotrophic factor (BDNF),
117	interleukin (IL)-1, IL-6 & IL-11, monoamine oxidase A (MAOA), 5-hydroxytryptamine
118	receptor (HTR1A/1B) and tryptophan hydroxylase 2 (TPH2). However, studies focusing
119	on genome-scale analyses of methylation are also emerging and have become more
120	frequent in the last few years ( $N=6$ ). The majority of such genome-scale efforts have
121	investigated pharmacological treatments of MDD as the treatment modality
122	( <i>N=4</i> )(Engelmann et al., 2022; Ju et al., 2019; Martinez-Pinteno et al., 2021; Takeuchi
123	et al., 2017) with only a few focused on ECT ( <i>N=2)(Moschny, Zindler, et al., 2020;</i>
124	Sirignano et al., 2021).
125	
126	3.1 Candidate gene DNAm studies investigating antidepressant response
127	The vast majority of candidate gene studies investigating DNAm patterns in
128	association with treatment outcomes are focused on pharmacological treatments for

selective serotonin reuptake inhibitors (SRRIs) (*N*=9), most studies include patients
undergoing a more heterogenous treatment regime utilizing a combination of tricyclic
antidepressants (TCAs), selective norepinephrine reuptake inhibitors (SNRIs), or
noradrenergic and specific serotonergic antidepressants (NaSSA), in addition to SRRIs.
Those pharmaco-epigenetic candidate gene studies can grant insights into DNAm

MDD. While some studies assess epigenetic marks associated with a response to

patterns of loci previously implicated in MDD and potentially be of predictive utility by
 characterizing DNAm patterns in those who respond or do not respond to a given
 treatment.

# 138 3.1.A Monoamine- transporters, oxidases, receptors & related genes

139

Among the first proposed hypotheses regarding the etiology of MDD was the 140 'monoamine theory' in which serotonin (5-HT), norepinephrine, and dopamine 141 deficiencies and imbalances were thought to underly the development of MDD (Coppen, 142 143 1967; Hamon & Blier, 2013; Schildkraut, 1965). Early findings from studies using monoamine oxidase inhibitors and TCAs potentiating 5-HT activity and in turn, 144 ameliorating depressive symptoms, have informed decades of research investigating 145 monoamine systems in MDD (reviewed in (Z. Li, Ruan, Chen, & Fang, 2021; Morilak & 146 Frazer, 2004)). As a result, a vast body of literature has investigated monoamine 147 neurotransmitter genes in MDD (reviewed in (Flint & Kendler, 2014; Shadrina et al., 148 2018). 149

The majority of such studies have analyzed genes in the serotonin pathway, e.g., 150 the serotonin transporter (SLC6A4) or serotonin receptor (HTR1A/1B). Many 151 152 antidepressant drugs exert their antidepressant effects by selectively inhibiting the function of SLC6A4 which is to mediate the reuptake of serotonin, a key 153 neurotransmitter in the brain. In addition, both serotonin receptor subtypes HTR1A and 154 155 HTR1B play a critical role in mediating antidepressant activity and have therefore been of great research interest (Fakhoury, 2015). The chronic administration of SSRIs 156 desensitizes the presynaptic HTR1A and HTR1B autoreceptors, decreasing the 157 negative feedback mediated by the receptors, and in turn, stimulating activation of post 158

159	synaptic serotonin receptors eliciting the antidepressant response (Chilmonczyk,
160	Bojarski, Pilc, & Sylte, 2015; Tiger, Varnas, Okubo, & Lundberg, 2018).

Concerning pharmaco-epigenetic studies investigating candidate genes, 161 SLC6A4 has been the most frequently assessed locus with six studies having 162 163 investigated differential DNAm associated with treatment outcomes following antidepressant treatment to date. All of the studies have examined CpGs in the 164 165 promoter region of SLC6A4. A number of early studies was conducted in populations of 166 Asian ancestry. The first study by Kang and colleagues (Kang et al., 2013) interrogated the methylation status of seven CpGs within the promoter of SLC6A4 in the peripheral 167 168 blood of 108 Korean patients, but only observed nominally significant differential 169 methylation (hypermethylation) of one CpG in treatment non-responders at baseline. A 170 study by Okada et al. (2014) conducted in Japan examined SLC6A4 promoter methylation in the peripheral blood of patients undergoing MDD treatment and 171 172 interrogated 81 CpGs in the SLC6A4 gene using a mass spectrometry approach. The authors identified hypermethylation of CpG 3 of SLC6A4 in treatment responders. A 173 similar effort in Japan (Iga et al., 2016) assessed SLC6A4 promoter methylation in 28 174 MDD patients undergoing treatment with various antidepressants including SSRIs and 175 TCAs for eight weeks. Akin to the earlier findings by Kang and colleagues (Kang et al., 176 2013), the authors identified the differential methylation of one CpG at baseline to be 177 178 nominally associated with treatment outcomes, however, Iga and colleagues describe their observations in relation to symptom improvement, with hypomethylation of one 179 180 CpG associated with improvement in symptom severity following eight weeks of treatment. 181

182 In contrast, Domschke and colleagues (2014) observed reduced SLC6A4 methylation across nine CpGs at baseline associated with an impaired response to 183 escitalopram treatment after six weeks in 94 patients of European descent suffering from 184 185 MDD. Interestingly, the seven previously investigated CpGs by Kang et al., showed the opposite direction of effect in this study: while Domschke et al. reported 186 hypomethylation to be associated with an inhibited treatment response in their 187 188 European cohort (Domschke et al., 2014), Kang and colleagues observed a relative increase in methylation—at least at one CpG site--to be associated with an impaired 189 improvement (Kang et al., 2013). Despite these contradictory findings, the findings by 190 191 Domschke and colleagues have since been supported in a recent observational study by Schiele et al. (2021), similarly investigating DNAm of nine CpG sites in the promoter 192 region of SLC6A4. The authors evaluated DNAm for its association with antidepressant 193 treatment response in the peripheral blood of 236 participants with MDD receiving 194 various antidepressants including SSRIs, SNRIs, TCAs and NaSSA over the six-week-195 long in-patient treatment. Their analysis of nine CpG sites by sequencing of bisulfite-196 converted DNA revealed that hypomethylation of several SLC6A4 CpGs was associated 197 with an impaired antidepressant response, as in the earlier work by Domschke and 198 199 colleagues. Their findings were replicated in another subset of patients that continued treatments with antidepressants (n= 110) (Schiele et al., 2021). 200

Overall, findings from studies investigating *SLC6A4* have been inconclusive with often contrasting results. The results of two studies (Iga et al., 2016; Kang et al., 2013) converge on findings of a negative correlation between promoter methylation and treatment outcomes, with Kang and colleagues reporting a trend of increased *SLC6A4* promoter CpG methylation associated with impaired treatment response while Iga and

206 colleagues reporting lower methylation associated with symptom improvement. Conversely, two studies (Domschke et al., 2014; Schiele et al., 2021) observed SLC6A4 207 hypomethylation in individuals unresponsive to antidepressant treatment while Okada 208 209 and colleagues found increased *SLC6A4* promoter methylation in treatment responders. Lastly, a study in Korea (Moon et al., 2022) investigated SLC6A4 promoter DNAm pre-210 and post-6 weeks of SSRI treatment but did not identify any Differentially methylated 211 212 positions (DMPs) associated with treatment response, further obscuring the predictive utility of SLC6A4 promoter methylation in relation to treatment outcomes. 213

Other genes of interest for pharmaco-epigenic studies in the serotonin pathway 214 include the Serotonin receptor subtypes (HTR1A/1B). Four studies to date have 215 216 investigated serotonin receptor subtype methylation level in association with MDD 217 treatment response. Akin to contradictions among results from studies of the serotonin transporter gene, there have been inconsistencies among the findings in studies of 218 219 HTR1A/1B. For example, a study by Gassó and colleagues (2017), investigated the 220 effects of DNAm and genetic variation of the 5-hydroxytryptamine receptor 1B (HTR1B) gene in relation to treatment response to the SSRI fluoxetine (Gasso et al., 2017). In 221 their study, 83 adolescent participants were evaluated for MDD (n=57), obsessive 222 compulsive disorder (n=16) and generalized anxiety disorder (n=12) symptoms 12 223 224 weeks into their fluoxetine treatment. The authors focused on the effect of SNPs in 225 transcription factor binding sites, proteins highly involved with the regulation of transcription and gene expression in the HTR1B locus, and clinical outcomes among 226 227 the patients. Their analysis found the two SNPs s9361233 and rs9361235, to be significantly associated with a positive treatment outcome after fluoxetine treatments. 228 Similarly, their DNAm analysis of 7 selected CpGs in the promoter region of HTR1B was 229

assessed via pyrosequencing and showed a negative correlation between positive
clinical outcomes after fluoxetine treatment and average *HTR1B* promoter region
methylation levels at baseline. However, the co-medication of some participants with
antipsychotics, mood stabilizers, and benzodiazepines limits the interpretability of the
results.

In contrast, Wang and colleagues (Wang, Lv, et al., 2018) focused on patients exclusively treated with escitalopram and observed hypomethylation at one CpG of *HTR1A* & and one CpG of *HTR1B* to be associated with an impaired respond to escitalopram. Additionally, the authors observed the interaction of recent stressful life events and hypomethylation at four CpG sites of *HTR1A/1B* to be associated with an impaired treatment response.

241

242

Another example is a recent study by Gao and colleagues (2022), who applied 243 neuroimaging and sequencing techniques to investigate brain activity and HTR1A/1B 244 DNAm with antidepressant treatment response in 300 patients to develop a model 245 capable of predicting treatment outcomes based on their data. Their analysis examined 246 over 116 different regions of the brain and 181 CpG sites located in the promoter region 247 248 of *HTR1A* and *HTR1B* while taking 11 clinical characteristics into account. Their logistic regression model resulted in 78.57% prediction accuracy with a 0.834 area under the 249 ROC curve (AUC). Of note, the methylation sites assessed in the study were in 250 251 proximity to the CpGs investigated in the earlier study by Wang et al (2018a (Wang, Lv, et al., 2018)) and showed similar lower methylation levels in the group resistant to 252

treatment, despite using a wide range of different antidepressants (SSRIs, SNRIs, and 253 254 NaSSAs). Finally, Xu and colleagues (Xu et al., 2022) focused their analysis on the impact of DNAm of HTR1A and HTR1B in combination with stressful life events and 255 256 childhood adversity on antidepressant treatment response. Stratifying their analysis into a SSRI and non-SSRI group, the authors assessed methylation in 181 CpG sites of the 257 HTR1A and HTR1B genes. Hypomethylation of one HTR1A CpG was associated with 258 259 an improved antidepressant response in patients of the non-SSRI group (treated with 260 SNRIs and NaSSAs). Additionally, the authors observed an interaction of HTR1A methylation at one CpG and childhood adversity, such that hyper methylation together 261 262 with high levels of childhood aversity, were significantly associated with poor treatment outcomes in both groups. Further, participants with the rs6298 SNP who also had high 263 methylation levels of HTR1B CpG3-61, showed significantly better efficacy of SSRI 264 treatment. 265

To date, studies of *HTR1A/1B CpG* methylation in relation to treatment outcomes are scarce, report contradicting directions of effect, and show heterogeneity in study designs, making comparisons among findings challenging. However, it is noteworthy that interaction of CpG methylation and genotype, or environmental effects such as stressful life events or childhood aversity, could jointly inform treatment outcomes as opposed to just by methylation alone.

272

273 An important regulator of monoamine levels is monoamine oxidases (MAOs) and 274 differential methylation of this locus has been assessed in the context of antidepressant 275 treatment response (Domschke et al., 2015). MAOs are enzymes located on the outer

276 membranes of mitochondria responsible for the metabolism of monoamine neurotransmitters via oxidative deamination (Yeung, Georgieva, Atanasov, & Tzvetkov, 277 2019). For instance, serotonin is degraded by MAO-A (Tong et al., 2013), and 278 279 consequently, inhibiting the activity of MAO-A by medications called monoamine oxidase inhibitors (MAOIs) is a well-established treatment approach in MDD. In a pilot 280 study, Domschke et al. investigated the relationship between DNAm of the monoamine 281 282 oxidase A (MAO-A) gene at 43 CpGs and escitalopram treatment response in a sample of 94, (61 females and 33 males)(Domschke et al., 2015). To account for MAO-A being 283 encoded on the X chromosome, the authors stratified their analysis by sex. The authors 284 285 did not observe any considerable influence of MAO-A methylation on treatment outcomes but hypomethylation at two CpGs in the MAO-A promoter region was 286 nominally associated with a treatment response in females. 287

Tryptophan hydroxylase-2 methylation (TPH2), another gene with important 288 regulatory functions regarding serotonin synthesis has also been investigated recently 289 (Shen et al., 2020). TPH2 is involved in limiting the rate of serotonin synthesis by 290 converting tryptophan to 5-hydroxytryptophan (Walther et al., 2003) and has been 291 explored within the context of psychiatric disorders (Ottenhof, Sild, Levesque, Ruhe, & 292 Booij, 2018), including MDD(Fan et al., 2021; S. J. Tsai et al., 2009; Zhang et al., 2015). 293 Shen and colleagues (2020) assessed DNAm of TPH2 in relation to antidepressant 294 295 treatment response in 291 participants (female n=187, male n =104) with MDD. The authors stratified their analysis by sex and identified one hypermethylated CpG site in 296 297 females and two in males to be nominally associated with an impaired treatment response. When assessing the impact of early life stress and DNAm on treatment 298 outcomes, the authors observed childhood adversity to be correlated with 299

300 hypomethylation of one CpG-site of TPH2 in males, which remained associated with an impaired treatment response after FDR correction. Participants with high levels of 301 302 childhood adversity had poorer treatment outcomes, leaving it unclear whether 303 treatment resistance was mediated by differential methylation or childhood adversity. 304 In summary, studies assessing DNAm of monoamine-related loci in relation to treatment outcomes in MDD have been inconclusive and present significant 305 306 methodological heterogeneity. The monoamine-related genes that are the focus of multiple independent studies, such as the serotonin transporter gene or its receptor 307 subtypes, report inconsistent and even contradicting directions of effects associated 308 with treatment outcomes. Interpretation of these efforts may be further complicated by 309 310 assessing different epigenetic loci, as well as heterogeneity in treatment regimens and 311 durations. These findings suggest future efforts are necessary in order to adequately assess the predictive potential of monoamine-related loci DNAm in MDD treatment 312 outcomes. 313

# 314 3.1.B Brain-derived neurotrophic factor (BDNF)

315

Another important pathway in MDD, and among the first ones to be examined in 316 a pharmaco-epigenetic context with a treatment response (Tadic et al., 2014), is the 317 318 neurotrophin Brain-derived neurotrophic factor (BDNF). BDNF has been extensively explored as a key molecular pathway in MDD involved in many synaptic and brain-319 related functions (Jin, Sun, Yang, Cui, & Xu, 2019), informing the neurotrophic 320 321 hypothesis of MDD by tying the pathogenesis of depression to alterations in BDNF expression and functioning (Kozisek, Middlemas, & Bylund, 2008). Altered BDNF levels 322 have been reported in patients with MDD in a number of studies(Bus et al., 2015; Kishi, 323

324 Yoshimura, Ikuta, & Iwata, 2017). The expression of *BDNF* and Tropomyosin receptor kinase B (TrkB) has been identified to be critical for the action of several 325 326 antidepressants (Casarotto et al., 2021; Castren & Monteggia, 2021) including SSRIs, TCAs, MAOIs, and ketamine, and alteration in the BDNF- TrkB multiprotein complex 327 has been found to interfere with the effects of antidepressants (Casarotto et al., 2021). 328 Additionally, BDNF plays a crucial role in other pathways implicated in MDD, due to its 329 330 role downstream of the monoamine signaling pathway (Tayyab et al., 2018), additionally rendering *BDNF* an attractive target for pharmaco-epigenomic studies. 331

To date, six candidate gene studies have examined DNAm of BDNF in relation to 332 333 antidepressant treatment response. Tadic and colleagues (2014) provided early 334 preliminary evidence that depressed patients with hypomethylation in the promoter region of BDNF are less likely to respond to antidepressant treatment(Tadic et al., 335 2014). In a pilot study, the authors investigated DNAm at 13 CpGs of the BDNF 336 promoter in the peripheral blood of 39 patients with MDD (female n= 22 male n = 17). 337 DNAm was assessed using a targeted DNAm approach using next-generation 338 sequencing of the bisulfite-converted DNA of the participants. Patients with lower 339 methylation at CpG site 87 of exon IV had a significantly lower treatment response to 340 fluoxetine and venlafaxine as compared to the participants showing higher methylation 341 342 at that locus. Later attempts to validate such findings by the same group in a sample of 561 patients did not confirm this finding in the overall sample, however, a subgroup of 343 199 patients with severe depression (HAM-17 scores  $\geq$  25) documented significantly 344 345 higher DNAm of that locus in treatment responders (Lieb et al., 2018). It's noteworthy that the treatment regime of participants in the pilot study (Tadic et al., 2014) included a 346 range of different antidepressants including SSRIs, SNRIs, and TCAs while the larger 347

study (Lieb et al., 2018) only included patients who were administered escitalopram or
venlafaxine.

These early findings of *BDNF* promoter methylation's positive association with 350 treatment outcomes have since been confirmed to hold potential in predicting 351 352 antidepressant treatment response in similar investigations by other groups(Hsieh, Lin, Lee, & Huang, 2019; L. Li et al., 2021; Wang, Zhang, et al., 2018). A clinical trial by 353 354 Wang and colleagues (Wang, Zhang, et al., 2018) investigated the association of BDNF 355 gene methylation and genotype with antidepressant treatment response in 85 patients with MDD. After eight weeks' treatment with the SSRI escitalopram, participants were 356 assessed for changes in their depressive symptoms. Hypomethylation in promoter-357 358 region CpG islands at baseline was associated with an impaired treatment response 359 compared to those who showed remission. Additionally, the authors document significantly better treatment outcomes in patients who had experienced fewer stressful 360 life events along with having *BDNF* hypermethylation. Similarly, Li and colleagues 361 (2021) examined the association of DNAm BDNF and response to antidepressant 362 treatment in MDD in 291 patients. The authors interrogated a total of 194 CpG sites at 363 baseline and observed significant hypermethylation of CpG 140 in the BDNF promotor 364 in female MDD remitters but not in males (L. Li et al., 2021) warranting further 365 366 examinations of sex-specific methylation patterns in relation to treatment response. 367 Relatedly, a smaller study conducted in Taiwan observed hypermethylation at one CpG of the BDNF exon IX promoter was associated with response to antidepressant 368 369 treatment in 25 responders(Hsieh et al., 2019). Conversely, a randomized control trial by Kim and colleagues documented the opposite direction of effect, in which BDNF 370 exon VI hypermethylation was associated with treatment resistance to 24 week-long 371

escitalopram administration, in 127 patients with comorbid acute coronary syndrome (J.
M. Kim et al., 2015). However, the clinical heterogeneity among the patients with regard
to cardiovascular pathologies and associated treatments limits the comparability of the
findings to other pharmaco-epigenetics studies of MDD.

Collectively, despite notable heterogeneity in study designs, five out of six studies focused on *BDNF* converge on identifying a pattern of significant association between promoter methylation and response to antidepressant treatment. While hypomethylation of *BDNF* promoter CpGs was indicative of impaired treatment outcomes in two independent studies (Tadic et al., 2014; Wang, Zhang, et al., 2018) hypermethylation of this locus has been associated with positive antidepressant responses in three studies (Hsieh et al., 2019; L. Li et al., 2021; Lieb et al., 2018).

383 3.1.C Interleukins

384

A large body of literature has characterized the role of inflammatory processes in 385 MDD (reviewed in (Beurel, Toups, & Nemeroff, 2020; Pariante, 2017)). Immune cell-386 mediated inflammation is a key mechanism to maintain homeostasis in the response to 387 harmful stimuli such as pathogens or cell damage and prolonged inflammatory immune 388 responses have been linked to MDD (Beurel et al., 2020). A range of proinflammatory 389 390 cytokines and their corresponding receptors have been associated with MDD (Petralia et al., 2020) including Interleukin (IL)-6, IL, IL-1β, IL-2, IL-4, IL-10, the IL-1, tumor 391 necrosis factor (TNF)- $\alpha$ , transforming growth factor- $\beta$ , and also C-reactive protein. Many 392 393 mechanisms contributing to inflammation in MDD have been proposed. These include the inflammasome pathway activated by heightened levels of damage-associated 394 molecular patterns (Fleshner, Frank, & Maier, 2017), oxidative stress (Bajpai, Verma, 395

Srivastava, & Srivastava, 2014), psychosocial stress (I. B. Kim, Lee, & Park, 2022), and diet (Lassale et al., 2019; Luo et al., 2023). Additionally, evidence from clinical trials further highlights the role of immune dysregulation in MDD (Bai et al., 2020; Wittenberg et al., 2020). Finally, the immune system's interrelation with the neuroendocrine system makes this pathway particularly relevant to MDD etiology and an important target for epigenetic treatment response prediction in MDD.

402 For example, an early randomized controlled trial by Powell and colleagues 403 (2013) (Powell et al., 2013) investigated DNAm of the *interleukin-11* (*IL11*) as a general 404 predictor of antidepressant treatment response in the peripheral blood of a sub-sample of 113 (female n = 67 male n = 46) participants with MDD. The patients were treated 405 406 with escitalopram (n=80) or the tricyclic antidepressant nortriptyline (n=33) for 12 407 weeks. Their analysis interrogated one CpG island, a region with a high number of CpG dinucleotide repeats, in *IL11* using a mass spectrometry approach. Their analysis 408 409 revealed that hypomethylation of IL11 CpG unit 5 was associated with an increased response to both administered treatments. Linear regression analysis assessing the 410 predictive potential of DNAm at any of the assessed CpGs revealed an interesting 411 contrast in the direction of the association of DNAm and treatment response: while 412 increased levels of baseline DNAm at IL11 unit 4 was found to be associated with a 413 414 higher treatment response among participants taking escitalopram, an impaired response was observed in those taking nortriptyline, pointing to medication-specific 415 difference. Such medication specific associations make a strong case to, if study design 416 417 permits, stratify future analysis in pharmaco-epigenetic studies by different antidepressant treatments. Additionally, the authors report that patients with higher IL11 418 methylation in combination with the rs1126757 allele had better antidepressant 419

420	responses by the end of treatment, providing evidence of how assessment of DNAm
421	and genotype can be combined to predict treatment outcomes in MDD.

422	Another recent pharmacogenetics study by Draganov et al., 2019 (Draganov et
423	al., 2019), investigated if the response to antidepressant treatment is associated with
424	DNAm of several inflammation-related genes. Similarly, they assessed if a treatment
425	response is associated with having inflammation-specific genetic variation (SNPs). The
426	authors identified 41 SNPs located in inflammation regulatory genes including
427	interleukin 1- $\beta$ , interleukin 2, 6, IL6R, IL10, IL18, tumor necrosis factor (TNF)- $\alpha$ , and
428	interferon (IFN)-γ. Subsequent pyrosequencing of five selected CpG Islands within IL1-
429	$\beta$ , <i>IL6,</i> and <i>IL6R</i> quantified the methylation status and revealed a higher methylation
430	percentage of <i>IL6R</i> CpG island to be associated with treatment response. SNPs in <i>IL1-<math>\beta</math></i>
431	and, marginally, <i>IL6R</i> were found to be in association with the treatment response to a
432	range of treatments including SSRIs, TCAs, MAOIs, mood stabilizers, and
433	antipsychotics. However, 56 of the patients were diagnosed with a range of comorbid
434	mental disorders including affective, anxiety, psychotic, and schizo-affective disorder at
435	baseline leaving the study findings to be interpreted with caution. In addition, the
436	authors did not control for heterogeneity in antidepressant treatment types and
437	dosages, further limiting the interpretability of the findings. In sum, findings from the two
438	candidate studies investigating interleukins are largely inconclusive, only nominally
439	significant (Draganov et al., 2019), and show significant heterogeneity in study design.

3.1.D Summary of Challenges associated with Candidate Gene Studies to Date
 441

442 Apart from the limited number of studies overall, there are several reasons 443 complicating the consistency between findings of candidate gene studies to date,

including: (1) The scope of assessed CpGs differs greatly. For example, in the above-444 described studies of SLC6A4, the number of CpGs investigated range between 7(Kang 445 et al., 2013) and 81 (Okada et al., 2014), with only Kang et al (Kang et al., 2013) and 446 447 Domschke et al (Domschke et al., 2014) and Schiele et al., 2021 (Schiele et al., 2021) examining some (n=7) of the same CpGs within that locus. Similarly, there has been 448 scarce convergence regarding assessed CpGs in studies assessing BDNF or serotonin 449 450 receptor subtypes, with only two studies (respectively, (Lieb et al., 2018; Tadic et al., 2014) & (Gao et al., 2022; Xu et al., 2022)) interrogating the same CpGs (2) The 451 pharmacological intervention in the studies is quite heterogeneous with only few studies 452 453 focusing on one SSRI alone(Wang, Lv, et al., 2018; Wang, Zhang, et al., 2018). Some studies augment SSRI treatment with antipsychotics, benzodiazepines and mood 454 stabilizers(Domschke et al., 2014; Gasso et al., 2017) while others incorporate a range 455 456 of SSRIs, SNRIs, and TCAs(L. Li et al., 2021; Okada et al., 2014; Schiele et al., 2019). Despite acknowledging the heterogeneity in medications among the patients, only a 457 limited number of studies stratify their analysis by different antidepressants(Domschke 458 et al., 2015; Powell et al., 2013; Xu et al., 2022) (3) Differences in allele frequencies of 459 assessed candidate loci. For example, SLC6A4 allele frequency differences(Ng et al., 460 2006) between Asian (Iga et al., 2016; Kang et al., 2013; Moon, Kim, Kim, Lim, & Kim, 461 2023: Okada et al., 2014) and Europeans (Domschke et al., 2014: Schiele et al., 2021) study 462 populations can also affect the observed methylation status (Giri et al., 2017) (4) The 463 treatment duration varies significantly. While the shortest treatment duration was about 464 2 weeks (Gao et al., 2022) the longest treatment course was up to 24 weeks(J. M. Kim 465 et al., 2015). The vast variation in treatment duration is also observed among studies 466 using a similar inventory of SSRIs, SNRIs, and TCAs, NaSSAs (Kang et al., 2013; L. Li 467

468	et al., 2021). (5) The majority of studies fail to address the potential confounding effect
469	of blood cell type heterogeneity. Only one recent candidate study (Shen et al., 2020)
470	included white blood cell proportion as a covariate in their analysis while the other
471	studies allowed the potential of observing inaccurate methylation patterns due to
472	differences in cell-type compositions in the blood samples of the participants. Of note,
473	many of these issues (2-5) apply not just to candidate gene studies, but also to
474	genome-scale studies, described in more detail below. Taken together, these
475	shortcomings illustrate the difficulty of consolidating findings from existing candidate
476	genes studies, rendering an assessment of their utility as biomarkers with predictive
477	potential likely premature.
478	
479	
480 481	3.3 Epigenome-wide association studies of response to antidepressants
482	Genome-scale studies have the potential to reveal novel loci and pathways
483	associated with MDD that have not been considered before in candidate gene
484	approaches. To date, only six studies have used a genome-scale approach to elucidate
485	the relationship between baseline DNAm and treatment outcomes in MDD of which four
486	efforts have been pharmaco-epigenetic studies (Engelmann et al., 2022; Ju et al., 2019;
487	Martinez-Pinteno et al., 2021; Takeuchi et al., 2017).
488	In a study from Japan, Takeuchi and Colleagues (2018) (Takeuchi et al., 2017)
489	investigated the potential of predicting the treatment response to paroxetine based on

490 genome-scale DNAm patterns in the peripheral blood of 68 MDD patients. In their

491 analysis, the authors contrasted the ten best responders and the ten worst responders to paroxetine treatment and identified the hypermethylation of the genes liprin-alpha-4 492 (PPFIA4) and heparan sulfate-glucosamine 3-sulfotransferase 1 (HS3ST1) at baseline 493 494 in patients with the worst treatment outcomes in relation to the best treatment responders (Takeuchi et al., 2017). The limited sample size of their study, not adjusting 495 for cell-type heterogeneity, along with the analytic approach of focusing exclusively on 496 497 selected best and worst responders to paroxetine treatment pose challenges to the interpretability of the findings as not every patient falls among the extremes of the 498 spectrum. Ju and colleagues investigated global DNAm changes in the blood of 499 500 responders (N = 82) and non-responder (N = 95) to the eight-week-long escitalopram treatment of 177 patients with MDD(Ju et al., 2019). Their analysis revealed 303 501 differentially methylated positions (DMPs) between treatment responders and non-502 503 responders at baseline at a nominal p-value (p < 0.05) with several differentially methylated CpG-site-associated differences in gene expression between the assessed 504 groups. One hypomethylated position in CHN2 showed the most significant association 505 with mRNA expression and was replicated in an external cohort. 506

507 Another small preliminary study of adolescents with MDD (Martinez-Pinteno et 508 al., 2021) assessed baseline DNAm differences in responders (N = 11) and non-509 responders (N = 11) before undergoing eight weeks of fluoxetine treatment. Considering 510 a difference in  $\beta$ -value medians of 0.2 the authors identified 21 DMPs between 511 treatment responders and the treatment-resistant group at baseline, predicting 512 treatment outcomes for MDD. Their small sample size limits the interpretability of the 513 findings; however, their data could be pooled together with future efforts.

514	A recent study profiled genome-scale baseline DNAm in responders and non-
515	responders to escitalopram, venlafaxine, and lithium treatment in 80 European MDD
516	patients (Engelmann et al., 2022). Despite the inability to identify any differentially
517	methylated positions on an epigenome- scale associated with treatment response, the
518	authors observed 18 hypermethylated and 2 hypomethylated regions associated with
519	positive treatment outcomes including one site in SORBS2 and CYP2C18.

- 520 Taken together, findings from genome-scale studies suggest that using 521 hypothesis-free approaches may be promising for identifying DNAm based
- 522 interindividual differences discerning treatment responders and non-responders.

## 523 3.4 Brain stimulation therapies (ECT, TMS)

524

Another alternative non-pharmacological treatment for MDD, which is now more 525 investigated for potential DNAm changes associated with treatment response, is brain 526 stimulation therapies such as ECT and TMS. TMS treatment involves stimulating the 527 brain via a magnetic field through the intact scalp. This exposure results in acute 528 529 depolarization and altered electrical activity in the underlying neurons; when applied repetitively, TMS alters the excitability of the surrounding region for a sustained period 530 outlasting the TMS exposure and is thought to exert its therapeutic effects through 531 532 altered cortical excitability (Jannati, Oberman, Rotenberg, & Pascual-Leone, 2023). To date, we have not identified any published studies examining the epigenetic profiles of 533 responders to TMS treatment however, a few studies (N = 5) have examined blood-534 derived DNAm profiles in relation to response to ECT in MDD. ECT treatment is a 535 procedure in which electric currents are applied to the brain resulting in brief and 536 controlled generalized seizures (M. Li et al., 2020). Although the mechanism of action 537

underlying ECT treatment remains elusive, findings from previous research converge on
attributing its therapeutic effects to augmentations in neuroplasticity (Deng et al., 2022;
Ousdal et al., 2022).

The first ECT-related study by Kleimann and colleagues (Kleimann et al., 2015) 541 542 reported lower levels of BDNF promoter I, IV, and VI CpGs in the peripheral blood of 11 MDD patients who remitted following treatment using targeted bisulfite-pyrosequencing. 543 544 The authors identified a negative correlation between mean *BDNF* promoter methylation 545 levels in the blood and BDNF serum levels which have previously been observed by 546 others (Boulle et al., 2012). A more recent study by Moshny and Colleagues (Moschny, Jahn, et al., 2020) investigated DNAm of two genes involved in the production of brain-547 548 derived neurotrophic factor (BDNF), t-PA and PAI-1, as potential biomarkers of ECT responsiveness when measured in peripheral blood; however, no differences in 549 baseline *t-PA* or *PAI-1* DNAm levels were detected between eventual ECT responders 550 551 vs. non-responders in either their first cohort (n=58) or in their second cohort (n=28). 552 Another preliminary study by the same research group (Moschny, Zindler, et al., 2020) assessed genome-scale DNAm in peripheral blood mononuclear cells longitudinally in a 553 small (n=12) cohort of patients with MDD, identifying eight novel candidate genes 554 implicated in the response to ECT treatment after analyzing the variance of every 555 differentially methylated probe including RNF175, RNF213, TBC1D14, TMC5, WSCD1 556 AC018685.2, AC098617.1, CLCN3P1. Further, the DNAm of two CpG sites within the 557 genes AQP10 and TRERF1 were found to change during treatment. 558

559 An ECT study by Sirignano and colleagues (Sirignano et al., 2021) examined the 560 effects of ECT treatment on DNAm associated with response status in a small sample

561 of depressed patients (n = 34). The authors assessed DNAm at baseline and also post completion of the treatment. In the binary response model of responders vs. non-562 responder status, one genome-scale differentially methylated CpG site was identified in 563 564 TNKS, a protein-coding gene involved in biological processes such as the Wnt signaling pathway and telomere length, both of which have previously been implicated in MDD 565 (Ridout, Ridout, Price, Sen, & Tyrka, 2016; Tayyab et al., 2018). Additionally, the author 566 567 identified two differentially methylated regions associated with reduction in depression measures. Subsequently, the authors investigated CpG sites in candidate genes 568 (n=799), previously implicated in the literature to be involved with DNAm in 569 570 antidepressant medication. However, their analysis of candidate CpGs associated with treatment ECT response revealed only one hypermethylated CpG in FKBP5 to be 571 significant after multiple test corrections in their continuous response model. 572 Taken together, the few studies examining genome-scale DNAm patterns in 573

association with response to ECT treatment are too scarce to infer any trends among
the suggested differentially methylated loci leaving plenty of opportunities for future
studies. Many of the identified loci, from the above-mentioned preliminary efforts,
require replication in more extensive cohorts of patients with MDD.

## 578 4. Discussion

579

580 The objective of this review was to synthesize existing literature characterizing 581 DNAm patterns associated with treatment outcomes of patients undergoing various 582 forms of treatment for MDD. The literature reviewed included several candidate gene 583 and genome-scale studies examining different treatment modalities for MDD including 584 various antidepressants and ECT. Overall, epigenetic studies investigating DNAm

585 associated with treatment responses are in their infancy with a limited number of studies that are frequently based on small sample sizes with inconsistent finding across studies. 586 Significant heterogeneity exists in study design, evaluated loci, tissue type examined, 587 588 methylation profiling approaches, treatment duration, dosage and type paired with other patient clinical characteristics, rendering premature any conclusions about the clinical 589 utility of implicated loci. The scarcity of existing studies and the inconsistent nature of 590 591 the results across studies suggests the need for more research into DNAm patterns associated with treatment outcomes; this is particularly true for non-pharmacological 592 approaches including brain stimulation therapies (e.g., TMS and ECT) and 593 594 psychotherapy, for which there remains a dearth of information in relation to response to those treatments in MDD. Limited evidence from a study of children with anxiety 595 disorders undergoing cognitive behavior theory (Roberts et al., 2014) observed changes 596 in SLC6A4 to be associated with treatment response, which gives hope for efforts to 597 characterize other treatment modalities that will follow. 598

Despite the lack of major convergence of differentially methylated loci among 599 most studies evaluating DNAm in relation to treatment response to MDD treatments, 600 BDNF perhaps emerges to be a notable exception. Hypomethylation of the BDNF 601 promoter has been implicated to be predictive of treatment non-response in two studies 602 603 with MDD patients (Tadic et al., 2014; Wang, Zhang, et al., 2018) while hypermethylation of this locus has been associated with treatment success in three 604 studies(Hsieh et al., 2019; L. Li et al., 2021) including one study with patients suffering 605 606 from severe MDD (Lieb et al., 2018). Interestingly, the positive association between BDNF promoter methylation and treatment responses has only been observed in 607 pharmacological treatment approaches. The only non-pharmacological study with 608

patients undergoing ECT treatment (Kleimann et al., 2015) observed the
hypomethylation of *BDNF* promoter CpGs among MDD remitters. Lastly, the finding of
Li and colleagues reporting significant hypermethylation of CpGs in *BDNF* in female
MDD remitters, but not in males, warrants further investigations into sex-specific DNAm
trends in relation to treatment response.

Another important finding from those initial studies is reports of medication-

specific differences in regards to DNAm associated with treatment response. Powel and

colleagues (2013) identified increased levels of baseline DNAm at IL11 unit 4

associated with a higher treatment response among participants taking escitalopram but

an impaired response in those on nortriptyline therapy (Powell et al., 2013). If replicated

by additional independent studies, such findings show the potential of pharmaco-

epigenetic studies in informing future treatment decisions, while also highlighting the

621 need for more comprehensive future studies that stratify patients into groups according

to their treatment, if various antidepressants are utilized.

This literature review revealed several challenges and methodological 623 considerations, that might hinder progress on the successful identification of predictive, 624 625 DNAm-based biomarkers with clinical utility. Chief among such challenges is the relative 626 instability of epigenetic marks in comparison to genetic variation. For example, genetic 627 assays like GWAS measure allele frequencies of genetic variants among study 628 participants that are consistent across various cell types and stable over time. On the 629 other hand, epigenetic marks such as DNA methylation are dynamic and susceptible to changes mediated by a range of environmental factors including aging, psychological 630 631 stress, and importantly, antidepressant medication (Moon et al., 2023; Wang, Zhang, et

632 al., 2018) and ECT (Moschny, Jahn, et al., 2020; Schurgers et al., 2022; Sirignano et al., 2021). Several studies document mechanisms in which psychotropic medications 633 can alter the epigenome, making controlling for such alteration an important 634 635 consideration (Bayles et al., 2013; Gassen et al., 2015). For example, with regard to DNAm, Gassen et al. demonstrated that the administration of paroxetine reduces the 636 phosphorylation and activity of DNA methyltransferase 1 in the peripheral blood of 637 638 patients with MDD(Gassen et al., 2015). Evidence from cell culture and murine studies suggests additional mechanisms in which antidepressant medications can influence the 639 epigenome by alterations to methyl-CpG-binding protein domains (Csoka & Szyf, 2009) 640 or chromatin remodelers (Qiao et al., 2019) while emerging literature documents the 641 effects of antidepressant treatments on the methylome (Mohammadi et al., 2022; Moon 642 et al., 2023; Wang, Zhang, et al., 2018). Similarly, emerging longitudinal ECT DNAm 643 studies observed alterations in DNAm in patients undergoing ECT (Moschny, Zindler, et 644 al., 2020; Schurgers et al., 2022; Sirignano et al., 2021). Overcoming these challenges 645 requires carefully designed longitudinal efforts that ideally assess epigenetic marks at 646 multiple timepoints. 647

Another substantial challenge in the development of biomarkers that could 648 predict treatment responses based on DNAm is the significant heterogeneity in cell-type 649 specific DNAm (Loyfer et al., 2023), making the selection of the tissue in which such 650 651 biomarkers are assessed an important consideration. This is particularly true for the assessment of psychiatric disorders like MDD, for which the organ central to the 652 653 disease, the brain, is not accessible in living patients. Therefore, investigators are limited to peripheral tissues such as blood, saliva, or buccal tissue. Despite some 654 progress in the characterization of the concordance between epigenetic alteration 655

656 observed in blood and in the brain (Braun et al., 2019; Hannon, Lunnon, Schalkwyk, & 657 Mill, 2015; Loyfer et al., 2023), the question of which tissue is most reflective of the brain remains to be answered by future studies. To overcome this challenge, 658 659 investigators could focus their efforts on CpGs with a high concordance between the peripheral tissue of choice and the brain, informed by consulting publicly available 660 resources such as the Epigenomics Roadmap Consortium (Roadmap Epigenomics et 661 662 al., 2015), the PsychENCODE knowledge portal (Psych et al., 2015) or web tools such as BECon (Edgar, Jones, Meaney, Turecki, & Kobor, 2017), Image-CpG (Braun et al., 663 2019) or wgbstools (Loyfer et al., 2023). All studies identified in this review, and the vast 664 665 majority of epigenetic studies investigating DNAm in general, have been conducted in peripheral blood. 666

Another important consideration is the limited scope of most DNAm treatment 667 response studies to date. The majority of conducted studies are candidate-gene studies 668 669 examining loci such as SLC6A4, BDNF, IL-1, IL-6 & IL-11, MAOA, HTR1A/1B, and 670 THH2. Although the investigated genes to date are central to many important pathways in depression such as monoamines, neurotrophins, and inflammation, it appears that 671 such pharmaco-epigenetic studies of the stress pathway are less represented. Figure 4 672 illustrates the genes and pathways assessed in extant candidate studies investigating 673 674 DNAm in relation to treatment responses. We identified only one candidate gene study (Maier et al., 2023) focused on loci of the stress pathway in the context of DNAm 675 studies investigating response to MDD treatments, despite stress being a well-studied 676 677 pathway in MDD pathophysiology. Stress exposure, especially during developmentally critical periods (Heim & Binder, 2012; Klengel et al., 2013), is the most well-678 characterized risk factor in MDD (Z. Li et al., 2021) and has also been extensively 679

680 studied in the context of epigenetics (Penner-Goeke & Binder, 2019). Stress exposure has been reported to induce structural changes in areas of the brain central to MDD 681 (McEwen, Nasca, & Gray, 2016) making the investigation of such loci in relation to their 682 683 association with a treatment response a plausible target for candidate gene studies. One of those loci could be FK506 binding protein 5 (FKBP5), an important regulator of 684 the HPA-axis crucial to the termination of the stress response by a negative feedback 685 686 loop. Genomic variations of this locus have previously been associated with HPA-axis alterations, recurrence of symptoms as well as response to treatment (Binder et al., 687 2004). Additionally, findings from cell-culture and animal studies, demonstrate the 688 689 breath of mechanism in which FKBP5 exerts its effect on this locus with other stressrelated pathways including BDNF (Gassen et al., 2015) and the immune system(Annett, 690 Moore, & Robson, 2020). Other genes that could serve as a potential target for 691 692 pharmaco-epigenetic studies focused on treatment response could be Corticotropinreleasing factor-binding protein (CRHB) or the glucocorticoid receptor (NR3C1) due to 693 their roles in the stress pathway and evidence from previous clinical studies 694 (Humphreys et al., 2019; Roy, Dunbar, Shelton, & Dwivedi, 2017). 695

Despite such opportunities for candidate gene studies, the application of 696 genome-scale approaches will be more appropriate to elucidate potentially new 697 biological pathways associated with MDD. Epigenome-wide association studies (EWAS) 698 could reveal novel epigenetic loci involved in treatment response. Smaller studies could 699 benefit from larger consortia efforts that combine data to have enough power to detect 700 701 epigenome-scale differences (P. C. Tsai & Bell, 2015). Another important consideration for genome-scale approaches is the heterogeneity in technologies used. While one 702 study (Takeuchi et al., 2017) used older array technology assessing 450,000 CpGs, four 703

704 studies employed the Epic Methylation array capable of interrogating 850,000 705 probes(Engelmann et al., 2022; Ju et al., 2019; Martinez-Pinteno et al., 2021; Sirignano et al., 2021). Moshny and Colleagues used the Nextseq 550 with EPIC kit capable of 706 707 interrogating over 3.3 million CpGs (Moschny, Zindler, et al., 2020). Such differences in the scope of the interrogated CpGs can make it difficult to compare findings, especially 708 among loci that are not covered by both of the above-mentioned microarrays. 709 710 Furthermore, the number of CpGs covered by current Illumina BeadChip platforms only accounts for around 3% of all GpG sites in the human genome (Bibikova et al., 2011) 711 712 leaving ample opportunities for future studies using whole-genome bisulfite sequencing 713 (WGBS). 714 An additional limitation that could potentially be addressed in the future by WGBS 715 studies is that studies to date have exclusively focused on DNAm at CpG dinucleotides. Compelling evidence reports on the wide distribution of cytosine methylation preceding 716 717 adenine, thymine, or other cytosine (non-CpG methylation) in several brain tissues (de 718 Mendoza et al., 2021) and neurons with non-CpG methylation accounting for as much as 25% of the methylation observed in neurons (Guo et al., 2014). WGBS studies offer 719 opportunities to identify methylation patterns important in the pathogenesis and 720 treatment response of MDD in previously unexplored loci including non-CpG 721 722 methylation.

### 723 **5. Conclusion**

724

It is evident that pharmaco-epigenetic studies characterizing DNAm patterns
 associated with treatment outcomes in MDD are in an early stage. Many efforts suffer
 from insufficient statistical power due to their limited sample sizes hindering the

detection of biomarkers with predictive utility. The majority of findings from previous 728 729 studies have yet to be replicated in independent cohorts suggesting that well-designed 730 studies investigating the DNAm associated with a treatment response have much to 731 contribute. Those studies will be most informative when multiple genomic measures are integrated into epigenetic studies of depression (Engelmann et al., 2022; Fuh, Fiori, 732 Turecki, Nagy, & Li, 2023; Ju et al., 2019; Wang, Lv, et al., 2018; Wang, Zhang, et al., 733 734 2018), in order to gain more wholistic insights into the functional relevance of observed epigenetic variation in MDD treatment response. Assessing DNAm at multiple 735 timepoints throughout the treatment could be particularly informative and perhaps bring 736 737 clinically significant opportunities. For example, DNAm profiled early in the course of a new intervention could elucidate methylation signatures that are associated with an 738 early treatment response or treatment resistance, and in turn, inform the likelihood of 739 remission at the end of the treatment. This would enable clinicians to be make timely 740 adjustments, sparing valuable time for patients, reduce suffering, mitigate the burden of 741 side effects, and cut healthcare expenditures. 742

In the future, well-designed studies may help elucidate additional biomarkers 743 that can predict MDD treatment response and potentially inform treatment options for a 744 patient suffering from treatment-resistant depression. The considerable cost of 745 conducting controlled clinical trials, environmental effects on the epigenome and inter-746 individual epigenomic variation pose challenges when it comes to efforts to reproduce 747 findings in larger cohorts. Findings from smaller studies should be considered 748 preliminary and should be replicated in larger cohorts. Larger collaborative efforts 749 including several sites are key to overcoming sample size limitations. Previous efforts 750 such as the STAR\*D project (Rush et al., 2004) are a good example of such 751

752	collaborative efforts. Additionally, there is increasing evidence that using predictive
753	models based on multimodal data fares much better in the prediction of treatment
754	outcomes than low-dimensional data (Gao et al., 2022; Lee et al., 2018). In this regard,
755	future efforts should integrate genetic information with epigenetic approaches to identify
756	more reliable prediction models. Approaches akin to the ones applied by Wang and
757	colleagues (Wang, Zhang, et al., 2018) in which life stress measures combined with
758	DNAm gave the best prediction of treatment response, or Powell and colleagues
759	reporting the interaction of <i>IL11</i> methylation and the rs1126757 variation (Powell et al.,
760	2013) are great examples of how multiple genetic, epigenetic and psychosocial
761	predictors can be combined to inform future response prediction tools. Similarly, multi-
762	omics study designs like the one employed by Ju and colleagues (Ju et al., 2019) or
763	Schurgers et al. (Schurgers et al., 2022), integrating DNAm measures with
764	transcriptomic data(Ju et al., 2019; Schurgers et al., 2022), can provide valuable
765	functional insights of MDD pathophysiology and inform about interplay between gene
766	expression and DNAm. Lastly, future efforts could expand on treatments other than
767	antidepressants and ECT by investigating DNAm in treatment responders undergoing
768	other forms of treatments such as TMS or psychotherapy, while also including
769	participants of ancestries beyond Europeans and Asians.

770

771

# 772 Acknowledgments and Disclosures

J. Dahrendorff was supported by the College of Public Health Doctoral Fellowship of the
University of South Florida. We would like to thank Allison Howard for her instructions
on effective literature searching for the students in the College of Public Health. Figures
1 and 4 created with BioRender (www.biorender.com)

# Figure Legends

Figure 1. Schematic representation of opportunities for pharmaco-epigenetic approaches in MDD treatment. Created with BioRender.com.

Figure 2. Literature search diagram showing the filtering and article selection process.

Figure 3. Increase of studies investigating DNAm signatures in MDD associated with a treatment response over the last decade.

Figure 4. Pathways of Significance in Pharmaco-epigenetic Studies of MDD Treatment Response and Opportunities for Future Efforts. Circles indicate candidate gene studies of a given loci that assessed DNAm in relation to treatment outcomes in patients treated using antidepressant medication. Triangles indicate studies that assessed DNAm in relation to outcomes in patients undergoing brain stimulation therapies. Created with BioRender.com.

# References

- Andersson, N. W., Gustafsson, L. N., Okkels, N., Taha, F., Cole, S. W., Munk-Jorgensen, P., & Goodwin, R. D. (2015). Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. *Psychol Med*, *45*(16), 3559-3569. doi:10.1017/S0033291715001488
- Annett, S., Moore, G., & Robson, T. (2020). FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention. *Pharmacol Ther*, *215*, 107623. doi:10.1016/j.pharmthera.2020.107623
- Arnaud, A. M., Brister, T. S., Duckworth, K., Foxworth, P., Fulwider, T., Suthoff, E. D., . . . Reinhart, M. L. (2022). Impact of Major Depressive Disorder on Comorbidities: A Systematic Literature Review. J Clin Psychiatry, 83(6). doi:10.4088/JCP.21r14328
- Association, A. P. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.). Washington, DC.
- Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., . . . Tang, Z. (2020). Efficacy and safety of antiinflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. *J Neurol Neurosurg Psychiatry*, 91(1), 21-32. doi:10.1136/jnnp-2019-320912
- Bajpai, A., Verma, A. K., Srivastava, M., & Srivastava, R. (2014). Oxidative stress and major depression. J Clin Diagn Res, 8(12), CC04-07. doi:10.7860/JCDR/2014/10258.5292
- Bayles, R., Baker, E. K., Jowett, J. B., Barton, D., Esler, M., El-Osta, A., & Lambert, G. (2013). Methylation of the SLC6a2 gene promoter in major depression and panic disorder. *PLoS One, 8*(12), e83223. doi:10.1371/journal.pone.0083223
- Beurel, E., Toups, M., & Nemeroff, C. B. (2020). The Bidirectional Relationship of Depression and Inflammation: Double Trouble. *Neuron*, 107(2), 234-256. doi:10.1016/j.neuron.2020.06.002
- Bibikova, M., Barnes, B., Tsan, C., Ho, V., Klotzle, B., Le, J. M., . . . Shen, R. (2011). High density DNA methylation array with single CpG site resolution. *Genomics*, *98*(4), 288-295. doi:10.1016/j.ygeno.2011.07.007
- Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Putz, B., . . . Muller-Myhsok, B. (2004).
   Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. *Nat Genet*, *36*(12), 1319-1325. doi:10.1038/ng1479
- Bjornsson, H. T., Sigurdsson, M. I., Fallin, M. D., Irizarry, R. A., Aspelund, T., Cui, H., . . . Feinberg, A. P. (2008). Intra-individual change over time in DNA methylation with familial clustering. *JAMA*, 299(24), 2877-2883. doi:10.1001/jama.299.24.2877
- Braun, P. R., Han, S., Hing, B., Nagahama, Y., Gaul, L. N., Heinzman, J. T., . . . Shinozaki, G. (2019).
   Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. *Transl Psychiatry*, 9(1), 47. doi:10.1038/s41398-019-0376-y
- Breitling, L. P., Yang, R., Korn, B., Burwinkel, B., & Brenner, H. (2011). Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. *Am J Hum Genet, 88*(4), 450-457. doi:10.1016/j.ajhg.2011.03.003
- Brunner, E. J., Shipley, M. J., Britton, A. R., Stansfeld, S. A., Heuschmann, P. U., Rudd, A. G., . . . Kivimaki, M. (2014). Depressive disorder, coronary heart disease, and stroke: dose-response and reverse causation effects in the Whitehall II cohort study. *Eur J Prev Cardiol, 21*(3), 340-346. doi:10.1177/2047487314520785
- Bus, B. A., Molendijk, M. L., Tendolkar, I., Penninx, B. W., Prickaerts, J., Elzinga, B. M., & Voshaar, R. C. (2015). Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. *Mol Psychiatry*, 20(5), 602-608. doi:10.1038/mp.2014.83

- Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., . . . Castren, E. (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. *Cell*, *184*(5), 1299-1313 e1219. doi:10.1016/j.cell.2021.01.034
- Castren, E., & Monteggia, L. M. (2021). Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. *Biol Psychiatry*, *90*(2), 128-136. doi:10.1016/j.biopsych.2021.05.008
- Cecil, C. A. M., Zhang, Y., & Nolte, T. (2020). Childhood maltreatment and DNA methylation: A systematic review. *Neurosci Biobehav Rev, 112*, 392-409. doi:10.1016/j.neubiorev.2020.02.019
- Chang, Z., Lichtenstein, P., Asherson, P. J., & Larsson, H. (2013). Developmental twin study of attention problems: high heritabilities throughout development. *JAMA Psychiatry*, *70*(3), 311-318. doi:10.1001/jamapsychiatry.2013.287
- Chilmonczyk, Z., Bojarski, A. J., Pilc, A., & Sylte, I. (2015). Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. *Int J Mol Sci, 16*(8), 18474-18506. doi:10.3390/ijms160818474
- Coppen, A. (1967). The biochemistry of affective disorders. *Br J Psychiatry*, *113*(504), 1237-1264. doi:10.1192/bjp.113.504.1237
- Csoka, A. B., & Szyf, M. (2009). Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. *Med Hypotheses, 73*(5), 770-780. doi:10.1016/j.mehy.2008.10.039
- de Mendoza, A., Poppe, D., Buckberry, S., Pflueger, J., Albertin, C. B., Daish, T., . . . Lister, R. (2021). The emergence of the brain non-CpG methylation system in vertebrates. *Nat Ecol Evol, 5*(3), 369-378. doi:10.1038/s41559-020-01371-2
- Deng, Z. D., Argyelan, M., Miller, J., Quinn, D. K., Lloyd, M., Jones, T. R., . . . Abbott, C. C. (2022). Electroconvulsive therapy, electric field, neuroplasticity, and clinical outcomes. *Mol Psychiatry*, 27(3), 1676-1682. doi:10.1038/s41380-021-01380-y
- Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F., 3rd. (2013). Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. *Br J Psychiatry*, 202(5), 329-335. doi:10.1192/bjp.bp.112.118307
- Domschke, K., Tidow, N., Schwarte, K., Deckert, J., Lesch, K. P., Arolt, V., . . . Baune, B. T. (2014). Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. *Int J Neuropsychopharmacol, 17*(8), 1167-1176. doi:10.1017/S146114571400039X
- Domschke, K., Tidow, N., Schwarte, K., Ziegler, C., Lesch, K. P., Deckert, J., . . . Baune, B. T. (2015). Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. *J Neural Transm (Vienna), 122*(1), 99-108. doi:10.1007/s00702-014-1227-x
- Draganov, M., Arranz, M. J., Salazar, J., de Diego-Adelino, J., Gallego-Fabrega, C., Jubero, M., . . . Portella, M. J. (2019). Association study of polymorphisms within inflammatory genes and methylation status in treatment response in major depression. *Eur Psychiatry*, 60, 7-13. doi:10.1016/j.eurpsy.2019.05.003
- Edgar, R. D., Jones, M. J., Meaney, M. J., Turecki, G., & Kobor, M. S. (2017). BECon: a tool for interpreting DNA methylation findings from blood in the context of brain. *Transl Psychiatry*, 7(8), e1187. doi:10.1038/tp.2017.171
- Engelmann, J., Zillich, L., Frank, J., Wagner, S., Cetin, M., Herzog, D. P., . . . Streit, F. (2022). Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial. *Transl Psychiatry*, *12*(1), 268. doi:10.1038/s41398-022-02032-7
- Fakhoury, M. (2015). New insights into the neurobiological mechanisms of major depressive disorders. *Gen Hosp Psychiatry, 37*(2), 172-177. doi:10.1016/j.genhosppsych.2015.01.005
- Fan, R., Hua, T., Shen, T., Jiao, Z., Yue, Q., Chen, B., & Xu, Z. (2021). Identifying patients with major depressive disorder based on tryptophan hydroxylase-2 methylation using machine learning algorithms. *Psychiatry Res, 306*, 114258. doi:10.1016/j.psychres.2021.114258

- Fleshner, M., Frank, M., & Maier, S. F. (2017). Danger Signals and Inflammasomes: Stress-Evoked Sterile Inflammation in Mood Disorders. *Neuropsychopharmacology*, 42(1), 36-45. doi:10.1038/npp.2016.125
- Flint, J. (2023). The genetic basis of major depressive disorder. *Mol Psychiatry*. doi:10.1038/s41380-023-01957-9
- Flint, J., & Kendler, K. S. (2014). The genetics of major depression. *Neuron, 81*(3), 484-503. doi:10.1016/j.neuron.2014.01.027
- Fuh, S. C., Fiori, L. M., Turecki, G., Nagy, C., & Li, Y. (2023). Multi-omic modeling of antidepressant response implicates dynamic immune and inflammatory changes in individuals who respond to treatment. *PLoS One, 18*(5), e0285123. doi:10.1371/journal.pone.0285123
- Gao, C., Xu, Z., Tan, T., Chen, Z., Shen, T., Chen, L., . . . Yuan, Y. (2022). Combination of spontaneous regional brain activity and HTR1A/1B DNA methylation to predict early responses to antidepressant treatments in MDD. *J Affect Disord*, *302*, 249-257. doi:10.1016/j.jad.2022.01.098
- Garcia-Gonzalez, J., Tansey, K. E., Hauser, J., Henigsberg, N., Maier, W., Mors, O., . . . Fabbri, C. (2017). Pharmacogenetics of antidepressant response: A polygenic approach. *Prog Neuropsychopharmacol Biol Psychiatry, 75*, 128-134. doi:10.1016/j.pnpbp.2017.01.011
- Gartlehner, G., Wagner, G., Matyas, N., Titscher, V., Greimel, J., Lux, L., . . . Lohr, K. N. (2017). Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. *BMJ Open*, 7(6), e014912. doi:10.1136/bmjopen-2016-014912
- Gassen, N. C., Fries, G. R., Zannas, A. S., Hartmann, J., Zschocke, J., Hafner, K., . . . Rein, T. (2015). Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. *Sci Signal, 8*(404), ra119. doi:10.1126/scisignal.aac7695
- Gasso, P., Rodriguez, N., Blazquez, A., Monteagudo, A., Boloc, D., Plana, M. T., . . . Mas, S. (2017). Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. *Prog Neuropsychopharmacol Biol Psychiatry*, *75*, 28-34. doi:10.1016/j.pnpbp.2016.12.003
- Giri, A. K., Bharadwaj, S., Banerjee, P., Chakraborty, S., Parekatt, V., Rajashekar, D., . . . Bharadwaj, D. (2017). DNA methylation profiling reveals the presence of population-specific signatures correlating with phenotypic characteristics. *Mol Genet Genomics, 292*(3), 655-662. doi:10.1007/s00438-017-1298-0
- Goodwin, R. D., Dierker, L. C., Wu, M., Galea, S., Hoven, C. W., & Weinberger, A. H. (2022). Trends in U.S. Depression Prevalence From 2015 to 2020: The Widening Treatment Gap. *Am J Prev Med*, *63*(5), 726-733. doi:10.1016/j.amepre.2022.05.014
- Guo, J. U., Su, Y., Shin, J. H., Shin, J., Li, H., Xie, B., . . . Song, H. (2014). Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. *Nat Neurosci, 17*(2), 215-222. doi:10.1038/nn.3607
- Hamon, M., & Blier, P. (2013). Monoamine neurocircuitry in depression and strategies for new treatments. *Prog Neuropsychopharmacol Biol Psychiatry*, 45, 54-63. doi:10.1016/j.pnpbp.2013.04.009
- Hannon, E., Lunnon, K., Schalkwyk, L., & Mill, J. (2015). Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. *Epigenetics*, *10*(11), 1024-1032. doi:10.1080/15592294.2015.1100786
- Hardeveld, F., Spijker, J., De Graaf, R., Hendriks, S. M., Licht, C. M., Nolen, W. A., . . . Beekman, A. T. (2013). Recurrence of major depressive disorder across different treatment settings: results from the NESDA study. *J Affect Disord*, *147*(1-3), 225-231. doi:10.1016/j.jad.2012.11.008
- Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018).
   Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States.
   JAMA Psychiatry, 75(4), 336-346. doi:10.1001/jamapsychiatry.2017.4602

- Heim, C., & Binder, E. B. (2012). Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. *Exp Neurol*, 233(1), 102-111. doi:10.1016/j.expneurol.2011.10.032
- Hou, L., Zhang, X., Wang, D., & Baccarelli, A. (2012). Environmental chemical exposures and human epigenetics. *Int J Epidemiol, 41*(1), 79-105. doi:10.1093/ije/dyr154
- Hsieh, M. T., Lin, C. C., Lee, C. T., & Huang, T. L. (2019). Abnormal Brain-Derived Neurotrophic Factor Exon IX Promoter Methylation, Protein, and mRNA Levels in Patients with Major Depressive Disorder. J Clin Med, 8(5). doi:10.3390/jcm8050568
- Humphreys, K. L., Moore, S. R., Davis, E. G., MacIsaac, J. L., Lin, D. T. S., Kobor, M. S., & Gotlib, I. H.
  (2019). DNA methylation of HPA-axis genes and the onset of major depressive disorder in adolescent girls: a prospective analysis. *Transl Psychiatry*, 9(1), 245. doi:10.1038/s41398-019-0582-7
- Iga, J., Watanabe, S. Y., Numata, S., Umehara, H., Nishi, A., Kinoshita, M., . . . Ohmori, T. (2016).
   Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder. *Hum Psychopharmacol*, 31(3), 193-199. doi:10.1002/hup.2527
- Jannati, A., Oberman, L. M., Rotenberg, A., & Pascual-Leone, A. (2023). Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation. *Neuropsychopharmacology, 48*(1), 191-208. doi:10.1038/s41386-022-01453-8
- Jia, H., Zack, M. M., Thompson, W. W., Crosby, A. E., & Gottesman, II. (2015). Impact of depression on quality-adjusted life expectancy (QALE) directly as well as indirectly through suicide. Soc Psychiatry Psychiatr Epidemiol, 50(6), 939-949. doi:10.1007/s00127-015-1019-0
- Jin, Y., Sun, L. H., Yang, W., Cui, R. J., & Xu, S. B. (2019). The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders. *Front Neurol*, *10*, 515. doi:10.3389/fneur.2019.00515
- Ju, C., Fiori, L. M., Belzeaux, R., Theroux, J. F., Chen, G. G., Aouabed, Z., . . . Turecki, G. (2019). Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. *Transl Psychiatry*, *9*(1), 254. doi:10.1038/s41398-019-0589-0
- Kang, H. J., Kim, J. M., Stewart, R., Kim, S. Y., Bae, K. Y., Kim, S. W., . . . Yoon, J. S. (2013). Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 44, 23-28. doi:10.1016/j.pnpbp.2013.01.006
- Kendler, K. S., Gatz, M., Gardner, C. O., & Pedersen, N. L. (2006). A Swedish national twin study of lifetime major depression. *Am J Psychiatry*, *163*(1), 109-114. doi:10.1176/appi.ajp.163.1.109
- Kendler, K. S., Ohlsson, H., Lichtenstein, P., Sundquist, J., & Sundquist, K. (2018). The Genetic Epidemiology of Treated Major Depression in Sweden. Am J Psychiatry, 175(11), 1137-1144. doi:10.1176/appi.ajp.2018.17111251
- Kim, I. B., Lee, J. H., & Park, S. C. (2022). The Relationship between Stress, Inflammation, and Depression. *Biomedicines*, 10(8). doi:10.3390/biomedicines10081929
- Kim, J. K., Samaranayake, M., & Pradhan, S. (2009). Epigenetic mechanisms in mammals. *Cell Mol Life Sci, 66*(4), 596-612. doi:10.1007/s00018-008-8432-4
- Kim, J. M., Stewart, R., Kang, H. J., Bae, K. Y., Kim, S. W., Shin, I. S., . . . Yoon, J. S. (2015). BDNF methylation and depressive disorder in acute coronary syndrome: The K-DEPACS and EsDEPACS studies. *Psychoneuroendocrinology*, 62, 159-165. doi:10.1016/j.psyneuen.2015.08.013
- Kishi, T., Yoshimura, R., Ikuta, T., & Iwata, N. (2017). Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses. *Front Psychiatry*, *8*, 308. doi:10.3389/fpsyt.2017.00308
- Kleimann, A., Kotsiari, A., Sperling, W., Groschl, M., Heberlein, A., Kahl, K. G., . . . Frieling, H. (2015).
   BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in depressed patients receiving electroconvulsive therapy. *J Neural Transm (Vienna), 122*(6), 925-928.
   doi:10.1007/s00702-014-1336-6

Klengel, T., & Binder, E. B. (2015). Epigenetics of Stress-Related Psychiatric Disorders and Gene x Environment Interactions. *Neuron*, *86*(6), 1343-1357. doi:10.1016/j.neuron.2015.036

 Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J. C., Pariante, C. M., . . . Binder, E. B. (2013). Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. *Nat Neurosci, 16*(1), 33-41. doi:10.1038/nn.3275

- Kozisek, M. E., Middlemas, D., & Bylund, D. B. (2008). Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. *Pharmacol Ther*, 117(1), 30-51. doi:10.1016/j.pharmthera.2007.07.001
- Kringel, D., Malkusch, S., & Lotsch, J. (2021). Drugs and Epigenetic Molecular Functions. A Pharmacological Data Scientometric Analysis. *Int J Mol Sci, 22*(14). doi:10.3390/ijms22147250
- Lassale, C., Batty, G. D., Baghdadli, A., Jacka, F., Sanchez-Villegas, A., Kivimaki, M., & Akbaraly, T. (2019). Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. *Mol Psychiatry*, *24*(7), 965-986. doi:10.1038/s41380-018-0237-8
- Lee, Y., Ragguett, R. M., Mansur, R. B., Boutilier, J. J., Rosenblat, J. D., Trevizol, A., . . . McIntyre, R. S. (2018). Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. J Affect Disord, 241, 519-532. doi:10.1016/j.jad.2018.08.073
- Li, L., Wang, T., Chen, S., Yue, Y., Xu, Z., & Yuan, Y. (2021). DNA methylations of brain-derived neurotrophic factor exon VI are associated with major depressive disorder and antidepressantinduced remission in females. *J Affect Disord*, *295*, 101-107. doi:10.1016/j.jad.2021.08.016
- Li, M., Yao, X., Sun, L., Zhao, L., Xu, W., Zhao, H., . . . Cui, R. (2020). Effects of Electroconvulsive Therapy on Depression and Its Potential Mechanism. *Front Psychol*, *11*, 80. doi:10.3389/fpsyg.2020.00080
- Li, Z., Ruan, M., Chen, J., & Fang, Y. (2021). Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. *Neurosci Bull, 37*(6), 863-880. doi:10.1007/s12264-021-00638-3
- Lieb, K., Dreimuller, N., Wagner, S., Schlicht, K., Falter, T., Neyazi, A., . . . Frieling, H. (2018). BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response. *Front Psychiatry*, *9*, 511. doi:10.3389/fpsyt.2018.00511
- Lotsch, J., Schneider, G., Reker, D., Parnham, M. J., Schneider, P., Geisslinger, G., & Doehring, A. (2013). Common non-epigenetic drugs as epigenetic modulators. *Trends Mol Med*, *19*(12), 742-753. doi:10.1016/j.molmed.2013.08.006
- Loyfer, N., Magenheim, J., Peretz, A., Cann, G., Bredno, J., Klochendler, A., . . . Kaplan, T. (2023). A DNA methylation atlas of normal human cell types. *Nature, 613*(7943), 355-364. doi:10.1038/s41586-022-05580-6
- Luo, L., Hu, J., Huang, R., Kong, D., Hu, W., Ding, Y., & Yu, H. (2023). The association between dietary inflammation index and depression. *Front Psychiatry*, 14, 1131802. doi:10.3389/fpsyt.2023.1131802
- Maier, H. B., Moschny, N., Eberle, F., Jahn, K., Folsche, T., Schulke, R., . . . Neyazi, A. (2023). DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy. *Pharmacopsychiatry*, *56*(2), 64-72. doi:10.1055/a-2034-6536
- Martinez-Pinteno, A., Rodriguez, N., Blazquez, A., Plana, M. T., Varela, E., Gasso, P., . . . Mas, S. (2021). DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results. *Pharmgenomics Pers Med*, *14*, 459-467. doi:10.2147/PGPM.S289480
- Martins, J., Czamara, D., Sauer, S., Rex-Haffner, M., Dittrich, K., Dorr, P., . . . Binder, E. B. (2021). Childhood adversity correlates with stable changes in DNA methylation trajectories in children and converges with epigenetic signatures of prenatal stress. *Neurobiol Stress*, *15*, 100336. doi:10.1016/j.ynstr.2021.100336

- Maugeri, A., & Barchitta, M. (2020). How Dietary Factors Affect DNA Methylation: Lesson from Epidemiological Studies. *Medicina (Kaunas), 56*(8). doi:10.3390/medicina56080374
- McEwen, B. S., Nasca, C., & Gray, J. D. (2016). Stress Effects on Neuronal Structure: Hippocampus, Amygdala, and Prefrontal Cortex. *Neuropsychopharmacology*, *41*(1), 3-23. doi:10.1038/npp.2015.171
- McGuffin, P., Rijsdijk, F., Andrew, M., Sham, P., Katz, R., & Cardno, A. (2003). The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. *Arch Gen Psychiatry*, *60*(5), 497-502. doi:10.1001/archpsyc.60.5.497
- Meerman, J. J., Ter Hark, S. E., Janzing, J. G. E., & Coenen, M. J. H. (2022). The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: A Systematic Review. J Affect Disord, 304, 1-11. doi:10.1016/j.jad.2022.02.015
- Moffitt, T. E., Caspi, A., Taylor, A., Kokaua, J., Milne, B. J., Polanczyk, G., & Poulton, R. (2010). How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. *Psychol Med*, *40*(6), 899-909. doi:10.1017/S0033291709991036
- Mohammadi, S., Beh-Pajooh, A., Ahmadimanesh, M., Amini, M., Ghazi-Khansari, M., Moallem, S. A., . . . Ghahremani, M. H. (2022). Evaluation of DNA methylation in BDNF, SLC6A4, NR3C1 and FKBP5 before and after treatment with selective serotonin-reuptake inhibitor in major depressive disorder. *Epigenomics*, 14(20), 1269-1280. doi:10.2217/epi-2022-0246
- Moon, Y. K., Kim, H., Kim, S., Lim, S. W., & Kim, D. K. (2023). Influence of antidepressant treatment on SLC6A4 methylation in Korean patients with major depression. *Am J Med Genet B Neuropsychiatr Genet*, *192*(1-2), 28-37. doi:10.1002/ajmg.b.32921
- Morilak, D. A., & Frazer, A. (2004). Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. *Int J Neuropsychopharmacol, 7*(2), 193-218. doi:10.1017/S1461145704004080
- Moschny, N., Jahn, K., Bajbouj, M., Maier, H. B., Ballmaier, M., Khan, A. Q., . . . Neyazi, A. (2020). DNA Methylation of the t-PA Gene Differs Between Various Immune Cell Subtypes Isolated From Depressed Patients Receiving Electroconvulsive Therapy. *Front Psychiatry*, *11*, 571. doi:10.3389/fpsyt.2020.00571
- Moschny, N., Zindler, T., Jahn, K., Dorda, M., Davenport, C. F., Wiehlmann, L., . . . Frieling, H. (2020). Novel candidate genes for ECT response prediction-a pilot study analyzing the DNA methylome of depressed patients receiving electroconvulsive therapy. *Clin Epigenetics*, *12*(1), 114. doi:10.1186/s13148-020-00891-9
- Neyazi, A., Theilmann, W., Brandt, C., Rantamaki, T., Matsui, N., Rhein, M., . . . Loscher, W. (2018). P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy. *Transl Psychiatry*, 8(1), 25. doi:10.1038/s41398-017-0077-3
- Ng, C. H., Easteal, S., Tan, S., Schweitzer, I., Ho, B. K., & Aziz, S. (2006). Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. *Prog Neuropsychopharmacol Biol Psychiatry*, 30(5), 953-957. doi:10.1016/j.pnpbp.2006.02.015
- Nishiyama, A., & Nakanishi, M. (2021). Navigating the DNA methylation landscape of cancer. *Trends Genet*, *37*(11), 1012-1027. doi:10.1016/j.tig.2021.05.002
- Okada, S., Morinobu, S., Fuchikami, M., Segawa, M., Yokomaku, K., Kataoka, T., . . . Mimura, M. (2014). The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. *J Psychiatr Res*, *53*, 47-53. doi:10.1016/j.jpsychires.2014.02.002
- Ottenhof, K. W., Sild, M., Levesque, M. L., Ruhe, H. G., & Booij, L. (2018). TPH2 polymorphisms across the spectrum of psychiatric morbidity: A systematic review and meta-analysis. *Neurosci Biobehav Rev, 92*, 29-42. doi:10.1016/j.neubiorev.2018.05.018
- Ousdal, O. T., Brancati, G. E., Kessler, U., Erchinger, V., Dale, A. M., Abbott, C., & Oltedal, L. (2022). The Neurobiological Effects of Electroconvulsive Therapy Studied Through Magnetic Resonance:

What Have We Learned, and Where Do We Go? *Biol Psychiatry*, *91*(6), 540-549. doi:10.1016/j.biopsych.2021.05.023

- Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006). Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. *Arch Gen Psychiatry*, *63*(5), 530-538. doi:10.1001/archpsyc.63.5.530
- Papakostas, G. I. (2008). Tolerability of modern antidepressants. *J Clin Psychiatry, 69 Suppl E1*, 8-13. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/18494538</u>
- Pariante, C. M. (2017). Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. *Eur Neuropsychopharmacol, 27*(6), 554-559. doi:10.1016/j.euroneuro.2017.04.001
- Penner-Goeke, S., & Binder, E. B. (2019). Epigenetics and depression Dialogues Clin Neurosci, 21(4), 397-405. doi:10.31887/DCNS.2019.21.4/ebinder
- Petralia, M. C., Mazzon, E., Fagone, P., Basile, M. S., Lenzo, V., Quattropani, M. C., . . . Nicoletti, F. (2020). The cytokine network in the pathogenesis of major depressive disorder. Close to translation? *Autoimmun Rev, 19*(5), 102504. doi:10.1016/j.autrev.2020.102504
- Powell, T. R., Smith, R. G., Hackinger, S., Schalkwyk, L. C., Uher, R., McGuffin, P., . . . Tansey, K. E. (2013).
   DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP.
   *Transl Psychiatry*, 3(9), e300. doi:10.1038/tp.2013.73
- Provencal, N., Arloth, J., Cattaneo, A., Anacker, C., Cattane, N., Wiechmann, T., . . . Binder, E. B. (2020). Glucocorticoid exposure during hippocampal neurogenesis primes future stress response by inducing changes in DNA methylation. *Proc Natl Acad Sci U S A*, *117*(38), 23280-23285. doi:10.1073/pnas.1820842116
- Psych, E. C., Akbarian, S., Liu, C., Knowles, J. A., Vaccarino, F. M., Farnham, P. J., . . . Sestan, N. (2015). The PsychENCODE project. *Nat Neurosci, 18*(12), 1707-1712. doi:10.1038/nn.4156
- Qiao, M., Jiang, Q. S., Liu, Y. J., Hu, X. Y., Wang, L. J., Zhou, Q. X., & Qiu, H. M. (2019). Antidepressant mechanisms of venlafaxine involving increasing histone acetylation and modulating tyrosine hydroxylase and tryptophan hydroxylase expression in hippocampus of depressive rats. *Neuroreport*, *30*(4), 255-261. doi:10.1097/WNR.00000000001191
- Ridout, K. K., Ridout, S. J., Price, L. H., Sen, S., & Tyrka, A. R. (2016). Depression and telomere length: A meta-analysis. *J Affect Disord*, *191*, 237-247. doi:10.1016/j.jad.2015.11.052
- Roadmap Epigenomics, C., Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., . . . Kellis, M. (2015). Integrative analysis of 111 reference human epigenomes. *Nature*, *518*(7539), 317-330. doi:10.1038/nature14248
- Roberts, S., Lester, K. J., Hudson, J. L., Rapee, R. M., Creswell, C., Cooper, P. J., ... Eley, T. C. (2014). Serotonin transporter [corrected] methylation and response to cognitive behaviour therapy in children with anxiety disorders. *Transl Psychiatry*, 4(9), e444. doi:10.1038/tp.2014.83
- Rotella, F., & Mannucci, E. (2013). Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. *J Clin Psychiatry*, 74(1), 31-37. doi:10.4088/JCP.12r07922
- Roy, B., Dunbar, M., Shelton, R. C., & Dwivedi, Y. (2017). Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder. *Neuropsychopharmacology*, 42(4), 864-875. doi:10.1038/npp.2016.175
- Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., . . . Group, S. D. I. (2004). Sequenced treatment alternatives to relieve depression (STAR\*D): rationale and design. *Control Clin Trials*, 25(1), 119-142. doi:10.1016/s0197-2456(03)00112-0
- Sailani, M. R., Halling, J. F., Moller, H. D., Lee, H., Plomgaard, P., Pilegaard, H., . . . Regenberg, B. (2019). Lifelong physical activity is associated with promoter hypomethylation of genes involved in metabolism, myogenesis, contractile properties and oxidative stress resistance in aged human skeletal muscle. *Sci Rep*, 9(1), 3272. doi:10.1038/s41598-018-37895-8

- Schiele, M. A., Kollert, L., Lesch, K. P., Arolt, V., Zwanzger, P., Deckert, J., . . . Domschke, K. (2019).
   Hypermethylation of the serotonin transporter gene promoter in panic disorder-Epigenetic imprint of comorbid depression? *Eur Neuropsychopharmacol, 29*(10), 1161-1167. doi:10.1016/j.euroneuro.2019.07.131
- Schiele, M. A., Zwanzger, P., Schwarte, K., Arolt, V., Baune, B. T., & Domschke, K. (2021). Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study. *Int J Neuropsychopharmacol, 24*(3), 191-199. doi:10.1093/ijnp/pyaa081
- Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. *Am J Psychiatry*, *122*(5), 509-522. doi:10.1176/ajp.122.5.509
- Schurgers, G., Walter, S., Pishva, E., Guloksuz, S., Peerbooms, O., Incio, L. R., . . . Rutten, B. P. F. (2022).
   Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy. *Eur Neuropsychopharmacol, 63*, 60-70. doi:10.1016/j.euroneuro.2022.07.183
- Shadrina, M., Bondarenko, E. A., & Slominsky, P. A. (2018). Genetics Factors in Major Depression Disease. *Front Psychiatry*, *9*, 334. doi:10.3389/fpsyt.2018.00334
- Shen, T., Li, X., Chen, L., Chen, Z., Tan, T., Hua, T., . . . Xu, Z. (2020). The relationship of tryptophan hydroxylase-2 methylation to early-life stress and its impact on short-term antidepressant treatment response. *J Affect Disord*, *276*, 850-858. doi:10.1016/j.jad.2020.07.111
- Sirignano, L., Frank, J., Kranaster, L., Witt, S. H., Streit, F., Zillich, L., . . . Foo, J. C. (2021). Methylome-wide change associated with response to electroconvulsive therapy in depressed patients. *Transl Psychiatry*, *11*(1), 347. doi:10.1038/s41398-021-01474-9
- Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., . . . Group for the Study of Resistant, D. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. *J Clin Psychiatry*, 68(7), 1062-1070. doi:10.4088/jcp.v68n0713
- Surtees, P. G., Wainwright, N. W., Luben, R. N., Wareham, N. J., Bingham, S. A., & Khaw, K. T. (2008).
   Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United
   Kingdom prospective cohort study. *Am J Psychiatry*, *165*(4), 515-523.
   doi:10.1176/appi.ajp.2007.07061018
- Tadic, A., Muller-Engling, L., Schlicht, K. F., Kotsiari, A., Dreimuller, N., Kleimann, A., . . . Frieling, H. (2014). Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. *Mol Psychiatry*, 19(3), 281-283. doi:10.1038/mp.2013.58
- Takeuchi, N., Nonen, S., Kato, M., Wakeno, M., Takekita, Y., Kinoshita, T., & Kugawa, F. (2017).
   Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation. *Neuropsychobiology*, *75*(2), 81-88. doi:10.1159/000480512
- Tayyab, M., Shahi, M. H., Farheen, S., Mariyath, M. P. M., Khanam, N., Castresana, J. S., & Hossain, M. M. (2018). Sonic hedgehog, Wnt, and brain-derived neurotrophic factor cell signaling pathway crosstalk: potential therapy for depression. *J Neurosci Res*, *96*(1), 53-62. doi:10.1002/jnr.24104
- Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T. J., Williams, C., . . . Wiles, N. (2013). Prevalence of treatment-resistant depression in primary care: cross-sectional data. *Br J Gen Pract, 63*(617), e852-858. doi:10.3399/bjgp13X675430
- Tiger, M., Varnas, K., Okubo, Y., & Lundberg, J. (2018). The 5-HT(1B) receptor a potential target for antidepressant treatment. *Psychopharmacology (Berl), 235*(5), 1317-1334. doi:10.1007/s00213-018-4872-1
- Tong, J., Meyer, J. H., Furukawa, Y., Boileau, I., Chang, L. J., Wilson, A. A., . . . Kish, S. J. (2013).
   Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab, 33(6), 863-871. doi:10.1038/jcbfm.2013.19

- Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., . . . Team, S. D. S. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*, *163*(1), 28-40. doi:10.1176/appi.ajp.163.1.28
- Tsai, P. C., & Bell, J. T. (2015). Power and sample size estimation for epigenome-wide association scans to detect differential DNA methylation. *Int J Epidemiol, 44*(4), 1429-1441. doi:10.1093/ije/dyv041
- Tsai, S. J., Hong, C. J., Liou, Y. J., Yu, Y. W., Chen, T. J., Hou, S. J., & Yen, F. C. (2009). Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. *Prog Neuropsychopharmacol Biol Psychiatry, 33*(4), 637-641. doi:10.1016/j.pnpbp.2009.02.020
- Undurraga, J., & Baldessarini, R. J. (2012). Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. *Neuropsychopharmacology*, *37*(4), 851-864. doi:10.1038/npp.2011.306
- van den Oord, C., Copeland, W. E., Zhao, M., Xie, L. Y., Aberg, K. A., & van den Oord, E. (2022). DNA methylation signatures of childhood trauma predict psychiatric disorders and other adverse outcomes 17 years after exposure. *Mol Psychiatry*, *27*(8), 3367-3373. doi:10.1038/s41380-022-01597-5
- van der Knaap, L. J., Riese, H., Hudziak, J. J., Verbiest, M. M., Verhulst, F. C., Oldehinkel, A. J., & van Oort, F. V. (2014). Glucocorticoid receptor gene (NR3C1) methylation following stressful events between birth and adolescence. The TRAILS study. *Transl Psychiatry*, 4(4), e381. doi:10.1038/tp.2014.22
- Vancampfort, D., Mitchell, A. J., De Hert, M., Sienaert, P., Probst, M., Buys, R., & Stubbs, B. (2015). Type
   2 Diabetes in Patients with Major Depressive Disorder: A Meta-Analysis of Prevalence Estimates and Predictors. *Depress Anxiety*, 32(10), 763-773. doi:10.1002/da.22387
- Walther, D. J., Peter, J. U., Bashammakh, S., Hortnagl, H., Voits, M., Fink, H., & Bader, M. (2003).
   Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science*, *299*(5603), 76. doi:10.1126/science.1078197
- Wang, P., Lv, Q., Mao, Y., Zhang, C., Bao, C., Sun, H., . . . Fang, Y. (2018). HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients. J Affect Disord, 228, 222-228. doi:10.1016/j.jad.2017.12.010
- Wang, P., Zhang, C., Lv, Q., Bao, C., Sun, H., Ma, G., . . . Cai, W. (2018). Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients. *Eur J Clin Pharmacol, 74*(8), 1011-1020. doi:10.1007/s00228-018-2463-z
- Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007). The STAR\*D Project results: a comprehensive review of findings. *Curr Psychiatry Rep, 9*(6), 449-459. doi:10.1007/s11920-007-0061-3
- Weaver, I. C., Meaney, M. J., & Szyf, M. (2006). Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. *Proc Natl Acad Sci U S A, 103*(9), 3480-3485. doi:10.1073/pnas.0507526103
- Wittenberg, G. M., Stylianou, A., Zhang, Y., Sun, Y., Gupta, A., Jagannatha, P. S., . . . Drevets, W. C. (2020). Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. *Mol Psychiatry*, 25(6), 1275-1285. doi:10.1038/s41380-019-0471-8
- Wong, C. C., Caspi, A., Williams, B., Craig, I. W., Houts, R., Ambler, A., . . . Mill, J. (2010). A longitudinal study of epigenetic variation in twins. *Epigenetics*, *5*(6), 516-526. doi:10.4161/epi.5.6.12226
- Xu, Z., Chen, Z., Shen, T., Chen, L., Tan, T., Gao, C., . . . Zhang, Z. (2022). The impact of HTR1A and HTR1B methylation combined with stress/genotype on early antidepressant efficacy. *Psychiatry Clin Neurosci, 76*(2), 51-57. doi:10.1111/pcn.13314

- Yeung, A. W. K., Georgieva, M. G., Atanasov, A. G., & Tzvetkov, N. T. (2019). Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. Front Mol Neurosci, 12, 143. doi:10.3389/fnmol.2019.00143
- Zhang, Y., Chang, Z., Chen, J., Ling, Y., Liu, X., Feng, Z., . . . Zhang, C. (2015). Methylation of the tryptophan hydroxylase-2 gene is associated with mRNA expression in patients with major depression with suicide attempts. *Mol Med Rep*, *12*(2), 3184-3190. doi:10.3892/mmr.2015.3748

# Tables

**Table 1.** Overview of studies characterizing DNA methylation profiles associated with treatment response in Major depressive disorder.

Author & Date	Sample	Antidepres sant	Treatme nt	Genomic Loci	Tissue Examined	Method to assess	Direction of Effect in Relation to
		Treatment	Duration	Assessed		Methylatio	Treatment Response
			and			n	
			Outcome				
			Measure				
Domschke et	94 MDD	Various	6 weeks,	9 CpGs of	Peripheral	Targeted	↓meth average ↓response
al. (2014)	(females	antidepressa	HAM-D%	SLC6A4	Blood	direct	mainly conferred by CpG 2
	n=61,	nts/Escitalop	change	exon 1A		bisulfite	(Bonferroni corrected)
	males n=	ram only				sequencing	
	33),	subsample				(measured	
	European	(n= 61)				at baseline)	
Demoskie at	ancestry	Mariaua	Currentia	42. On On in	Denimbenel	Townstad	trand for Longth in two On Co
Domschke et	94 MDD	various	6 Weeks,		Peripheral	Targeted	trend for Umeth in two CpGs
al. (2015)	(lemales	antidepressa	HAIVI-D%	MAU-A	ыююа	bisulfito	(nominally significant)
	males n=	Fscitalopram	change			sequencing	(noninally significant)
	33)	- only				(measured	
	European	subsample				at baseline)	
	ancestry	(n=61)				at success)	
Dragonov et	155 MDD	Various	4 weeks,	5 CpG sites	Peripheral	Bisulfite-	↑meth <i>IL6R</i> CpG ↑response
al. (2019)	(females	antidepressa	Response	of <i>IL6,</i> 6	Blood	pyrosequen	(nominally significant)
	n=105,	nts	= MSM ≤7	sites of IL1-		cing	
	males			β		(measured	
	n=48),			and 2 of		at baseline)	
	European			IL6R			
	ancestry						
Engelmann et	80 MDD	Escitalopram	4 weeks,	EWAS/	Whole	Illumina	No epigenome-scale
al. (2022)	(temale	, vanlafavina	HAM-D%	Genome-	DIOOD	EPIC	significant differentially
	11-40, molog n=	lithium	change	scale		beauchip (maggurad	Amoth DMPs 2 moth
	34)	nunum				(measureu	DMRs: strongest in
	European					at baseline)	SORBS2 CVP2C18
	ancestry						↑response (Šidák corrected)
Gao et al.	98 MDD	Various	2 weeks.	181 CpGs	Peripheral	Bisulfite	meth HTR1A CpG 208 &
(2022)	(female	antidepressa	HAM-D%	sites of	Blood	Amplicon	HTR1B CpG 65 tresponse
	n=55, male	nts	change	HTR1A and		Sequencing	(nominally significant)
	n=43),		Ű	HTR1B.		(measured	
	Asian					at baseline)	
	ancestry						

Gasso et al. (2017)	57 MDD, (no sex breakdown of participants in MDD cohort) adolescents between 10-17 years, European ancestry	Fluoxetine, comedicatio n with antipsychotic s & (or) benzodiazep ines or mood stabilizers	12 weeks, CDI change	7 CpG sites in <i>HTR1B</i> promoter	Peripheral Blood	Bisulfite- pyrosequen cing (measured at baseline)	↓meth <i>HTR1B</i> promoter ↑response (nominally significant)
Hsieh et al. (2019)	51 MDD, 62 controls (female n=25 male n=25 in case and controls), Asian ancestry	Various antidepressa nts & benzodiazep ines	4 weeks, HAM-D% change	14 CpG sites in <i>BDNF</i> exon IX	Peripheral Blood	Bisulfite- pyrosequen cing (measured at baseline)	↑meth <i>BDNF</i> CpG 24 & CpG 324 ↑response (nominally significant)
lga et al. (2016)	28 MDD, (female n=20, male n=8), Asian ancestry	Various antidepressa nts	8 weeks, HAM-D% change	9 CpG sites in <i>SLC6A4</i> promoter	Peripheral Blood	Bisulfite- pyrosequen cing (measured at baseline & completion of treatment)	trend for ↓meth <i>SLC6A4</i> CpG 2 ↑response (Bonferroni corrected)
Ju et al. (2019)	177 MDD (female n=110 male, n= 67), Majority of European ancestry	Escitalopram	8 weeks, MADRS% change	EWAS/ Genome- scale	Peripheral Blood	Infinium Methylation EPIC Beadchip (measured at baseline)	↓meth two DMP in <i>CHN2</i> and one in DMP in <i>JAK2</i> ↑response, one DMP in <i>CHN2</i> replicated in an external cohort
Kang et al. (2013)	108 MDD (female n=75 male, n=33), Asian ancestry	Various antidepressa nts	12 weeks, HAM-D% change	7 CpGs in SLC6A4 promoter	Peripheral Blood	Bisulfite- pyrosequen cing (measured at baseline)	trend for ↑meth CpG 2 ↓response (nominally significant)
Kleimann et al. (2015)	11 patients (female n=5, male n=6), European ancestry	ECT	3.5 weeks, MADRS% change, BDI-II change	BDNF promoter I, IV, and VI CpGs	Peripheral Blood	Bisulfite- pyrosequen cing (measured at baseline, throughout & after treatment)	↓meth <i>BDNF</i> exon I promoter ↑response (nominally significant)
Kim et al. (2015)	127 MDD & acute coronary syndrome (no sex breakdown of participants in MDD	Escitalopram	24-weeks, HAM-D% change	9 CpGs sites in <i>BDNF</i> exon VI	Peripheral Blood leukocytes	Bisulfite- pyrosequen cing (measured at baseline & completion of treatment)	↑meth one <i>BDNF CpG</i> & average ↓response

	cohort), Asian ancestry						
Li et al. (2021)	291 MDD (female n=189, male n=102), Asian ancestry	Various antidepressa nts( SSRIs, SNRIs, NaSSAs, SARIs)	6 weeks, HAM-D% change	194 CpG sites spanning six CpG Islands of <i>BDNF</i>	Peripheral Blood	Targeted NGS-based methylation analysis (measured at baseline)	↑meth <i>BDNF</i> CpG 140 ↑response (FDR corrected)
Lieb et al. (2018)	561 MDD (female n=315, male n=246) [199 Severe MDD HAM- 17 scores ≥ 25 (female n=118, male n=81), European ancestry	Escitalopram for 2 weeks, venlafaxine in non- responders, lithium added after 28 days in non- responders	8 weeks, HAM-D% change	BDNF Exon IV promoter and p11 promoter	Peripheral Blood	Targeted direct bisulfite sequencing (measured at baseline)	↑meth <i>BDNF</i> CpG-87 in patients with severe MDD ↑response (uncorrected for multiple testing)
Maier et al. (2023)	31 MDD (female n=20, male n=11), European ancestry	ECT	3-4 weeks, BDI-II and MADRS% change	43 CpG Sites in <i>NR3C1</i> and 28 CpG Sites in <i>POMC</i>	PBMCs	Sanger sequencing of bisulfite- converted DNA Bisulfite- pyrosequen cing (measured at baseline, throughout & after treatment)	↓meth <i>NR3C1</i> ↑response (nominally significant)
Martinez- Pinteño et al. (2021)	22 MDD (female n=19, male n=3), children and adolescents between 13-17 years, European ancestry	Fluoxetine	8 weeks, CDI%- & CGI-I% change	EWAS/ Genome- scale	Peripheral Blood	Illumina Infinium Methylation EPIC BeadChip (measured at baseline)	↑meth CpG sites <i>RHOJ</i> & ↓meth <i>OR2L13</i> ↓response (FDR corrected)
Moon et al. (2022)	221 MDD (female n=173, male n=48), Asian ancestry	Various SSRIs (Escitalopra m, Fluoxetine, Paroxetine, Sertraline	6 weeks, HAM-D% change	Nine CpG sites in the promoter region of <i>SLC6A4</i>	Peripheral blood	Bisulfite- pyrosequen cing (measured at baseline & completion of treatment)	No DMPs identified ↑meth CpG4, ↓meth CpG3 & CpG5 observed after treatment completion (nominally significant)

Moschny et al. (2020)a	87 MDD (female n=45, male n=42), European ancestry	ECT	HAM-D% Change, MADRS% change	39 CpG sites in <i>t-PA</i> and 35 CpGs in <i>PAI-1</i>	PBMCs	Sanger sequencing of bisulfite- converted DNA (measured at baseline, throughout & after treatment)	No differences in baseline t- PA or PAI-1 meth (Šidák corrected)
Moschny et al. (2020)b	17 MDD (female n=10, male n=7), European ancestry	ECT	4 weeks, BDI-II and MADRS% change	EWAS/ Genome- scale	PBMCs	Illumina NextSeq 550 (measured at baseline & completion of treatment)	↓meth <i>RNF175</i> , ↑meth <i>RNF213</i> , ↓meth <i>TBC1D14</i> , ↑meth <i>TMC5</i> , ↑meth <i>WSCD1</i> , ↓meth <i>AC018685.2</i> , ↓meth <i>AC098617.1</i> , ↑meth <i>CLCN3P1</i> ↑ response
Okada et al. (2014)	50 MDD 50 controls (female n=25, male n=25 in case and controls), Asian Ancestry	Paroxetine, fluvoxamine, milnacipran	6 weeks, HAM-D% change	81 CpGs in SLC6A4 promoter	Peripheral Blood	Targeted methylation array (measured at baseline & completion of treatment)	↑meth <i>SLC6A4</i> CpG 3 ↑response (Bonferroni corrected)
Powell et al. (2013)	113 MDD (female n=67, male n=46), European ancestry	80 Escitalopram , 33 Nortriptyline	12 weeks, MADRS% change	CpG island of <i>interleukin-</i> 11 loci.	Peripheral Blood	Targeted methylation assessmen t (measured at baseline)	↓meth CpG 5 ↑ response ↑meth CpG4 ↑response ↑meth CpG 11 x rs1126757 GG ↑response (FDR corrected)
Sirignano et al. (2021)	34 MDD (female n=16, male n=18), European ancestry	ECT	HAM-D% change	EWAS/ Genome- scale & 799 candidate gene CpGs	Peripheral Blood	Illumina Infinium Methylation EPIC array (measured at baseline & completion of treatment)	↑meth <i>FKBP5</i> CpG at follow- up ↑response in continuous response model (FDR corrected) No differences in baseline meth after correction for multiple comparisons)
Schiele et al. (2021)	236 MDD (female n=138, male n= 98) European ancestry	Various anti- depressants	6 weeks, HAM-D% change	9 CpG sites located in the <i>SLC6A4</i> promoter region	Blood cells	Direct sequencing of sodium bisulfite- treated DNA (measured at baseline)	↓meth CpG ↓response, similar trend in longitudinal replication cohort (n=110) (nominally significant)
Shen et al. (2020)	291 MDD (female n=187, male n=104) 1000 healthy controls,	Various anti- depressants	HAM-D% Change, 2 weeks	38 CpG sites of <i>TPH2</i>	Peripheral blood	NGS-based multiple Targeted CpG methylation analysis method	<pre>↑meth 2 CpGs in male &amp; ↑meth 1 CpG in female ↓response (uncorrected for multiple testing) ↑meth 2 CpGs x ↑ early life stress ↓response (FDR corrected)</pre>

	Asian ancestry					(measured at baseline)	
Tadic et al. (2014)	39 MDD, (female n=22, male n=17) European ancestry	Fluoxetine, Venflaxine, TCAs	6 weeks, HAM-D% change	12 CpG sites of <i>BDNF</i> exon IV promoter	PBMCs	Direct sequencing of sodium bisulfite– treated DNA	↓meth CpG 87 at baseline ↓response
Takeuchi et al. (2018)	20 MDD (female n=11, male n=9), Asian ancestry	Paroxetine	6 weeks, HAM-D% change	EWAS/ Genome- scale	Peripheral Blood	Infinium HumanMet hylation450 BeadChip (measured at baseline)	↑meth <i>PPFIA4</i> CpG cg00594917 ↑meth <i>HS3ST1</i> CPG cg07260927 ↓response (FDR corrected)
Wang et al. (2018)a	85 MDD (female n=56, male n=29), Asian ancestry	Escitalopram & low dose of benzodiazep ines	8 weeks, HAM-D% change	96 CpG sites in HTR1A & HTR1B promoter	Peripheral blood	Bisulfite Amplicon Sequencing (measured at baseline & completion of treatment)	↓meth <i>HTR1A1</i> CpG 668 & <i>HTR1B1</i> CpG 1401 ↓response ↑meth <i>HTR1A1</i> CpG 668 x Life Events Scale score ↓response (FDR corrected)
Wang et al. (2018)b	85 MDD (female n=56, male n=29), 44 longitudinal, Asian ancestry	Escitalopram & low dose of benzodiazep ines	8 weeks, HAM-D% change	90 CpG sites in BDNF	Peripheral blood	Bisulfite Amplicon Sequencing (measured at baseline & completion of treatment)	↑meth <i>BDNF</i> at four amplicons in <i>BDNF</i> ↑response ↓average meth <i>BDNF</i> ↓response ↓Stressful life events x ↑meth ↑response (FDR corrected)
Wang et al. (2022)	291 MDD patients (female n=189, male n=102) & 100 controls (female n=64, male n=36), Asian ancestry	Various Antidepress ants (SSRI- group & non- SSRI-group)	2 weeks, HAM-D% change	74 CpG sites of <i>P11</i>	Peripheral blood	Bisulfite Amplicon Sequencing (measured at baseline)	↑meth <i>P11-3-185 x</i> early life stress ⊥response (FDR corrected)
Xu et al. (2022)a	291 MDD patients (female n=189, male n=102) & 100 controls (female n=64, male n=36), Asian ancestry	Various Antidepress ants (SSRI- group & non- SSRI-group)	2 weeks, HAM-D% change	181 CpGs sites of <i>HTR1A</i> and <i>HTR1B</i> .	Peripheral blood	Bisulfite Amplicon Sequencing (measured at baseline)	↓meth <i>HTR1A-2</i> CpG 143 + low CTQ score ↑response ↑meth <i>HTR1B</i> CpG 3-61 x <i>rs6298</i> AA/AG genotype ↑response
Xu et al. (2022)b	87 MDD (female n=72, male n=15) & 53 controls (female	Various Antidepress ants	6 weeks, BDI-II ≤ 10	3 CpGs of RPS6KA5	Peripheral blood	Bisulfite- pyrosequen cing (measured at baseline)	∱average meth ↑response (Benjamini- Hochberg adjusted)

n=39 male			
n=14) Asian			
ancestry			

### Notes and abbreviations

MDD = Major Depressive Disorder

DNAm = DNA Methylation; PBMCs = Peripheral blood mononuclear cells

CpG site/CpGs = regions of DNA where a cytosine nucleotide is followed by a guanine

nucleotide in the linear sequence of bases along its  $\mathbf{5}' \to \mathbf{3}'$  direction

DMP = Differentially methylated position; DMR = Genomic regions with different DNA methylation status across different samples

SSRIs = Selective serotonin reuptake inhibitors; SNRIs = Serotonin–norepinephrine reuptake inhibitors; TCAs = Tricyclic antidepressants; NaSSAs = Noradrenergic and specific serotonergic antidepressants, SARIs = Serotonin antagonist and reuptake inhibitors; ECT = Electroconvulsive therapy

 $\uparrow$ meth = hypermethylation,  $\downarrow$ meth = hypomethylation,

↑response = treatment responders, ↓response = treatment non-responders

HAM-D = Hamilton Rating Scale for Depression, CES-D = Center for Epidemiologic Studies Depression, CDI = Children's Depression Inventory, CGI-S = Clinical Global Impression-Severity scale, GAF = Global Assessment of Functioning Scale, CGAS = Children's global Assessment Scale, MADRS = Montgomery Åsberg Depression Rating Scale, BDI-II = Beck's Depression Inventory, CTQ = Childhood Trauma Questionnaire, MSM = Maudsley Staging Met

# Figures

Figure 1. Schematic representation of opportunities for pharmaco-epigenetic approaches in MDD treatment.









**Figure 3.** Increase of studies investigating DNAm signatures in MDD associated with a treatment response over the last decade



**Figure 4.** Pathways of Significance in Pharmaco-epigenetic Studies of MDD Treatment Response and Opportunities for Future Efforts.